var title_f19_4_19520="Basic case 9 with answer";
var content_f19_4_19520=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Atrial flutter to sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 80px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spontaneous conversion of atrial flutter (note the regular flutter waves) with variable degrees of atrioventricular block to normal sinus rhythm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_4_19520=[""].join("\n");
var outline_f19_4_19520=null;
var title_f19_4_19521="Cutaneous horn eyelid";
var content_f19_4_19521=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous horn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from Slomovits, TL (Ed), Basic and clinical science courses section, American Academy of Ophthalmology, San Francisco 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_4_19521=[""].join("\n");
var outline_f19_4_19521=null;
var title_f19_4_19522="TempTest temp threshold";
var content_f19_4_19522=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F80086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F80086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Temperature thresholds in cold urticaria patients can be determined by Temp",
"    <em>",
"     Test",
"    </em>",
"    &reg;",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Temp",
"    <em>",
"     Test",
"    </em>",
"    &reg; can be used to determine individual temperature thresholds in patients with urticaria. The critical temperature threshold is defined as the highest temperature used for skin provocation testing that can elicit a wheal reaction. Critical temperature thresholds in the test reaction sites and patients shown are 20&deg;C (A), 16&deg;C (B), and 14&deg;C (C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marcus Maurer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_4_19522=[""].join("\n");
var outline_f19_4_19522=null;
var title_f19_4_19523="Overview of hematopoiesis";
var content_f19_4_19523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F60964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F60964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 573px\">",
"   <div class=\"ttl\">",
"    Hematopoietic stem cells, cytokines, and cellular maturation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 553px; height: 539px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hierarchical relationship of pluripotent hematopoietic stem cells (PHSC), progenitors, and mature cells together with major cytokine sources and actions. Cells of the bone marrow microenvironment such as macrophages, endothelial cells, and reticular fibroblastoid cells produce M-CSF, GM-CSF, G-CSF, IL-6, and probably Steel factor (SF) after induction with endotoxin or IL-1/TNF. T-cells produce IL-3, GM-CSF, and IL-5 in response to antigenic and IL-1 stimulation. These cytokines have overlapping actions during hematopoietic differentiation, as indicated, and, for most lineages, optimal development requires a combination of early- and late-acting factors.",
"    <div class=\"footnotes\">",
"     MSC: myeloid stem cell; CFU-MEG: megakaryocyte colony-forming unit; other abreviations are explained in the text.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_4_19523=[""].join("\n");
var outline_f19_4_19523=null;
var title_f19_4_19524="Endotracheal tube positioning";
var content_f19_4_19524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55694%7EPULM%2F68470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55694%7EPULM%2F68470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endotracheal tube positioning",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagrammatic representation of key distances related to endotracheal tube positioning. Malpositioning of the endotracheal tube can be suspected from the depth of insertion. In the average adult, the 18-24 cm mark will show at the incisors when the tip of the tube is midway between the vocal cords and the carina.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Stone, DJ, Bogdonoff, DL, Anesth Analg 1992; 74:276.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Endotracheal tube with movement of the neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 218px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A shows the position of the tip of the endotracheal tube with the neck in neutral position. The tip of the tube follows the movement of the chin. The tube moves away from the carina with extension of the neck (B) and toward the carina with flexion (C) of the neck.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_4_19524=[""].join("\n");
var outline_f19_4_19524=null;
var title_f19_4_19525="Major side effects of gold";
var content_f19_4_19525=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Major side effects of gold",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/4/19525/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/4/19525/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/4/19525/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/4/19525/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/4/19525/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/4/19525/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/4/19525/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 9, 2009.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gold is used in the treatment of rheumatoid arthritis (RA) and other rheumatic diseases (eg, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis with polyarthritis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25319?source=see_link\">",
"     \"Use of gold compounds in rheumatic diseases\"",
"    </a>",
"    .) Its use, however, may be limited by a number of potential toxic effects. This topic will review the major side effects of the gold compounds, how to monitor for toxicity, and treatment of adverse reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TOXICITY OF GOLD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gold can adversely affect many different organ systems (",
"    <a class=\"graphic graphic_table graphicRef61137 \" href=\"UTD.htm?13/56/14222\">",
"     table 1",
"    </a>",
"    ). Some of these reactions are dependent upon the type of gold used and the immunogenetic characteristics of the patient. The following general observations have been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adverse reactions develop in about one-third of patients with RA treated with intramuscular gold [",
"      <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. The most common complications are dermatitis, stomatitis, transient hematuria, and mild proteinuria. These side effects occur less commonly with oral gold (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/47/31476?source=see_link\">",
"       auranofin",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/3\">",
"       3",
"      </a>",
"      ]. By contrast, diarrhea is more typically seen with auranofin.",
"     </li>",
"     <li>",
"      Gold-induced proteinuria and thrombocytopenia occur more frequently in patients with RA who possess HLA-DR3 [",
"      <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/4\">",
"       4",
"      </a>",
"      ]; this antigen is found in most reported patients with gold-induced thrombocytopenia. The HLA-DQA region genes may also be important in patients with RA; one study, for example, demonstrated that they confer susceptibility for gold nephropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Postinjection reactions may be the rapid-onset vasomotor type, or the slower-onset non-vasomotor type. Vasomotor (nitritoid) reactions, characterized by weakness, dizziness, nausea, vomiting, sweating, and facial flushing, typically follow",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/15/41204?source=see_link\">",
"       gold sodium thiomalate",
"      </a>",
"      (GSTM) injections [",
"      <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/6\">",
"       6",
"      </a>",
"      ]. Hypertensive patients with RA who take angiotensin converting enzyme (ACE) inhibitors may develop nitritoid reactions after oral gold or injections [",
"      <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. GSTM is best given with the patient recumbent since vasomotor reactions occur soon after injection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately 15 percent of patients treated with GSTM develop non-vasomotor postinjection reactions, associated with transient arthralgia, joint swelling, fatiguability, and malaise. The reaction begins within hours after injection, and lasts one to two days.",
"   </p>",
"   <p>",
"    Gold compounds should",
"    <strong>",
"     never",
"    </strong>",
"    be administered to patients with a history of severe toxicity. Ordinarily, gold is not given to pregnant or lactating women because safety for the fetus or infant is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mucocutaneous effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatitis and stomatitis account for most adverse gold reactions. Gold rashes are highly variable and may mimic many other skin conditions. Typically, the rash is characterized by discrete pruritic lesions affecting the limbs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    trunk that last one to two months. These reactions are seen about three-fold less in patients taking gold sodium thioglucose (GSTG) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/9\">",
"     9",
"    </a>",
"    ]. This is a worldwide concern because of the loss of market availability of GSTG [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/10\">",
"     10",
"    </a>",
"    ]. For example, withdrawal of GSTG in Holland led to the use of only GSTM. Twelve months after this switch, 24 percent of patients in one cohort had withdrawn from GSTM because of inefficacy or mucocutaneous side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/9\">",
"     9",
"    </a>",
"    ]. Moreover, the use of Q-switch laser hair removal treatment in someone previously treated with gold may cause disfiguring hyperpigmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nephrotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient proteinuria, microscopic hematuria, and nephrotic syndrome are well-described complications of gold therapy. Renal biopsy usually reveals membranous nephropathy, but minimal change disease has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=see_link\">",
"     \"Causes and diagnosis of membranous nephropathy\"",
"    </a>",
"    .) The prognosis for gold-associated proteinuria is favorable. Mild proteinuria may resolve spontaneously even with continuation of gold, while reversal of nephrotic syndrome requires the cessation of gold therapy. Complete resolution of proteinuria requires an average of 11 months and may take as long as two to three years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/12\">",
"     12",
"    </a>",
"    ]. Once the proteinuria clears, injections may be safely restarted at a 50 percent lower dose [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lack of resolution suggests some other cause for the nephrotic syndrome. This includes secondary amyloidosis or rarely membranous nephropathy due to RA itself. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37812?source=see_link\">",
"     \"Renal disease in patients with rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hematologic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major hematologic complications of gold therapy: thrombocytopenia; agranulocytosis; and pancytopenia. Thrombocytopenia is a rare (1 to 3 percent of patients) complication of gold treatment that may be life threatening. Easy bruisability or petechiae may develop shortly after gold is started, or as long as 18 months after it is stopped. Marrow suppression can occur, but the thrombocytopenia is usually due to immune destruction of platelets associated with an active marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Those patients who develop thrombocytopenia after parenteral gold may develop it again with other second-line agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link&amp;anchor=H8#H8\">",
"     \"Drug-induced thrombocytopenia\", section on 'Gold salts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Agranulocytosis is an unusual complication that can occur with parenteral or oral gold therapy. The duration of granulocytopenia is variable. The worst complication of gold is severe pancytopenia or bone marrow aplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The incidence of this problem is less than 0.5 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Interstitial pneumonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial pneumonitis associated with diffuse pulmonary infiltration is a rare complication that is seen after a total dose of about 500 mg of gold [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Rapid improvement usually follows withdrawal of gold and the administration of systemic glucocorticoids. This response to therapy and certain other clinical features distinguishes gold-induced lung disease from that due to RA itself. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34918?source=see_link\">",
"     \"Gold-induced pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30344?source=see_link\">",
"     \"Drug-induced lung disease in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Gastrointestinal tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enterocolitis is an uncommon but serious complication of parenteral gold [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/22\">",
"     22",
"    </a>",
"    ]. Symptoms include nausea, vomiting, abdominal pain, profuse diarrhea, and fever. Despite supportive treatment, mortality approaches 50 percent.",
"   </p>",
"   <p>",
"    A mild enterocolitis, characterized by diarrhea, is twice as common in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/47/31476?source=see_link\">",
"     auranofin",
"    </a>",
"    than intramuscular gold. This observation may be explained by the fact that about 85 percent of oral gold is eliminated in the feces.",
"   </p>",
"   <p>",
"    Cholestatic jaundice with elevated transaminases and high alkaline phosphatase levels has uncommonly been ascribed to gold [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/23\">",
"     23",
"    </a>",
"    ]. Pancreatitis is also a rare benign complication [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neurologic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic complications of chrysotherapy are rare and reversible. Typical findings include peripheral neuropathy, a Guillain-Barr&eacute;-type syndrome, cranial nerve palsies including ophthalmoplegia, and encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/25\">",
"     25",
"    </a>",
"    ]. Neurologic toxicity arises after three months of weekly injections; myokymia (irregular muscle twitching) is a characteristic clinical sign. Diagnostic confusion may arise because the neuropathy induced by gold can resemble some features of rheumatoid neuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Monitoring for toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough history, including drug reactions, rash, renal disease, or proteinuria, should be sought prior to beginning therapy. Some problems, such as preexisting renal disease, preclude the use of gold. A baseline complete blood count with differential, platelet count, urinalysis, and biochemical profile should be obtained. Blood work and urinalysis for protein are obtained at least every two weeks during induction and monthly for maintenance therapy. The patient may keep a diary of blood counts and urinalyses as a double check to the danger signals of cytopenias or proteinuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT OF GOLD TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When one of the above toxic reactions occurs, etiologies such as laboratory error, incidental skin or mucous membrane lesions, side effects from other medications, or extraarticular features of RA should be considered. Without any other good explanation, however, the reaction is considered gold-related and chrysotherapy is terminated immediately. Most adverse reactions resolve spontaneously weeks or months after stopping gold. As noted above, the nephrotic syndrome is an exception; proteinuria make increase for one to two months after cessation of therapy and complete resolution often takes more than one year [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mucocutaneous reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with gold dermatitis benefit from antihistamines or topical corticosteroids. Systemic glucocorticoids can be used for more severe generalized rashes, while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    (Betnasol) pellets sucked three or four times a day may be beneficial in patients with mouth ulcers. Sun and soap should be avoided.",
"   </p>",
"   <p>",
"    Chrysotherapy should be stopped until the rash clears. Treatment may be restarted using a reduced dosage schedule of 5 to 10 mg of gold weekly, with 5 to 10 mg increments every 1 to 4 weeks if no reaction occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Severe reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious complications require more aggressive therapy and",
"    <strong>",
"     preclude",
"    </strong>",
"    further use of chrysotherapy. Moderate to high dose glucocorticoid therapy (20 to 60 mg daily in divided doses) may be beneficial in gold-induced thrombocytopenia, bone marrow toxicity, enterocolitis, and pulmonary infiltrates.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/42/9893?source=see_link\">",
"     Dimercaprol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    , N-acetylcysteine, and other chelating agents have been used to treat reactions unresponsive to glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/1\">",
"     1",
"    </a>",
"    ], while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    may be effective for severe enterocolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with severe thrombocytopenia and hemorrhage may require volume expansion and platelet transfusions.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     Vincristine",
"    </a>",
"    , other potent chemotherapeutic agents, splenectomy, and more recently intravenous immune globulin also have been used to treat this problem [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Significant agranulocytosis often improves spontaneously within two weeks. Bone marrow aplasia is a life-threatening complication that must be treated aggressively. The prognosis of marrow aplasia has been improved by the use of antithymocyte globulin&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/17,29\">",
"     17,29",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) can be given for severe neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19525/abstract/29\">",
"     29",
"    </a>",
"    ]. Younger patients may require bone marrow transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29930?source=see_link\">",
"     \"Aplastic anemia: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H454321627\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors of UpToDate, Inc. would like to acknowledge Duncan Gordon, MD (deceased), who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Gordon, DA, Klinkhoff, AV. Second line agents: Sulfasalzine, antimalarials, gold and penicillamine. In: Kelley's textbook of rheumatology, 7th ed, Ruddy, S, Harris, ED, Sledge, CB (Eds), WB Saunders, Philadelphia 2005. p.877.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/2\">",
"      van Jaarsveld CH, Jahangier ZN, Jacobs JW, et al. Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis. Rheumatology (Oxford) 2000; 39:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/3\">",
"      Abruzzo JL. Auranofin: a new drug for rheumatoid arthritis. Ann Intern Med 1986; 105:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/4\">",
"      Wooley PH, Griffin J, Panayi GS, et al. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med 1980; 303:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/5\">",
"      Sakkas LI, Chikanza IC, Vaughan RW, et al. Gold induced nephropathy in rheumatoid arthritis and HLA class II genes. Ann Rheum Dis 1993; 52:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/6\">",
"      Ho M, Pullar T. Vasomotor reactions with gold. Br J Rheumatol 1997; 36:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/7\">",
"      Healey LA, Backes MB. Nitritoid reactions and angiotension-converting-enzyme inhibitors. N Engl J Med 1989; 321:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/8\">",
"      Nixon J, Pande I. Gold, nitritoid reactions and angiotensin-converting enzyme inhibitors. Rheumatology (Oxford) 2006; 45:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/9\">",
"      van Roon EN, van de Laar MA, Janssen M, et al. Parenteral gold preparations. Efficacy and safety of therapy after switching from aurothioglucose to aurothiomalate. J Rheumatol 2005; 32:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/10\">",
"      Klinkhoff A. An editorial is a golden opportunity. J Rheumatol 2005; 32:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/11\">",
"      Almoallim H, Klinkhoff AV, Arthur AB, et al. Laser induced chrysiasis: disfiguring hyperpigmentation following Q-switched laser therapy in a woman previously treated with gold. J Rheumatol 2006; 33:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/12\">",
"      Hall CL, Fothergill NJ, Blackwell MM, et al. The natural course of gold nephropathy: long term study of 21 patients. Br Med J (Clin Res Ed) 1987; 295:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/13\">",
"      Klinkhoff AV, Teufel A. Reinstitution of gold after gold induced proteinuria. J Rheumatol 1997; 24:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/14\">",
"      Adachi JD, Bensen WG, Kassam Y, et al. Gold induced thrombocytopenia: 12 cases and a review of the literature. Semin Arthritis Rheum 1987; 16:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/15\">",
"      von dem Borne AE, Pegels JG, van der Stadt RJ, et al. Thrombocytopenia associated with gold therapy: a drug-induced autoimmune disease? Br J Haematol 1986; 63:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/16\">",
"      Wijnands MJ, Allebes WA, Boerbooms AM, et al. Thrombocytopenia due to aurothioglucose, sulphasalazine, and hydroxychloroquine. Ann Rheum Dis 1990; 49:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/17\">",
"      Yan A, Davis P. Gold induced marrow suppression: a review of 10 cases. J Rheumatol 1990; 17:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/18\">",
"      Kay AG. Myelotoxicity of gold. Br Med J 1976; 1:1266.",
"     </a>",
"    </li>",
"    <li>",
"     Gordon, DA, Hyland, RH, Broder, I. Rheumatoid arthritis. In: The Lung in Rheumatic Diseases, Cannon, GW, Zimmerman, GA (Eds), Marcel Dekker, New York, 1990, pp. 229-259.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/20\">",
"      Tomioka R, King TE Jr. Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease. Am J Respir Crit Care Med 1997; 155:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/21\">",
"      Libby D, White DA. Pulmonary toxicity of drugs used to treat systemic autoimmune diseases. Clin Chest Med 1998; 19:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/22\">",
"      Fam AG, Paton TW, Shamess CJ, Lewis AJ. Fulminant colitis complicating gold therapy. J Rheumatol 1980; 7:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/23\">",
"      Watkins PB, Schade R, Mills AS, et al. Fatal hepatic necrosis associated with parenteral gold therapy. Dig Dis Sci 1988; 33:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/24\">",
"      Eisemann AD, Becker NJ, Miner PB Jr, Fleming J. Pancreatitis and gold treatment of rheumatoid arthritis. Ann Intern Med 1989; 111:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/25\">",
"      Fam AG, Gordon DA, Sarkozi J, et al. Neurologic complications associated with gold therapy for rheumatoid arthritis. J Rheumatol 1984; 11:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/26\">",
"      Klinkhoff AV, Teufel A. How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions. J Rheumatol 1995; 22:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/27\">",
"      Wolfe F. The curious case of intramuscular gold. Rheum Dis Clin North Am 1993; 19:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/28\">",
"      Dorta G, Schnegg JF, Saraga E, Schmied PA. Treatment of gold-induced enteritis with octreotide. Lancet 1993; 342:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19525/abstract/29\">",
"      Collins DA, Tobias JH, Hill RP, Bourke BE. Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF). Br J Rheumatol 1993; 32:518.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7510 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-E8883028DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_4_19525=[""].join("\n");
var outline_f19_4_19525=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TOXICITY OF GOLD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mucocutaneous effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hematologic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Interstitial pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neurologic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Monitoring for toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT OF GOLD TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mucocutaneous reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Severe reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454321627\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7510\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7510|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/56/14222\" title=\"table 1\">",
"      Toxicity of gold compounds",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29930?source=related_link\">",
"      Aplastic anemia: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=related_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30344?source=related_link\">",
"      Drug-induced lung disease in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=related_link\">",
"      Drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34918?source=related_link\">",
"      Gold-induced pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37812?source=related_link\">",
"      Renal disease in patients with rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25319?source=related_link\">",
"      Use of gold compounds in rheumatic diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_4_19526="Terbinafine (systemic): Pediatric drug information";
var content_f19_4_19526=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Terbinafine (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34358?source=see_link\">",
"    see \"Terbinafine (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/46/9957?source=see_link\">",
"    see \"Terbinafine (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9566188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      LamISIL&reg;;",
"     </li>",
"     <li>",
"      Terbinex&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9480131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Terbinafine&reg;;",
"     </li>",
"     <li>",
"      Auro-Terbinafine;",
"     </li>",
"     <li>",
"      CO Terbinafine;",
"     </li>",
"     <li>",
"      Dom-Terbinafine;",
"     </li>",
"     <li>",
"      GD-Terbinafine;",
"     </li>",
"     <li>",
"      JAMP-Terbinafine;",
"     </li>",
"     <li>",
"      Lamisil&reg;;",
"     </li>",
"     <li>",
"      Mylan-Terbinafine;",
"     </li>",
"     <li>",
"      Nu-Terbinafine;",
"     </li>",
"     <li>",
"      PHL-Terbinafine;",
"     </li>",
"     <li>",
"      PMS-Terbinafine;",
"     </li>",
"     <li>",
"      Q-Terbinafine;",
"     </li>",
"     <li>",
"      Riva-Terbinafine;",
"     </li>",
"     <li>",
"      Sandoz-Terbinafine;",
"     </li>",
"     <li>",
"      Teva-Terbinafine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10526800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34358?source=see_link\">",
"      see \"Terbinafine (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Tinea capitis:",
"     </b>",
"     Children &ge;4 years and Adolescents: Oral: Granules",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &lt;25 kg: 125 mg once daily for 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     25-35 kg: 187.5 mg once daily for 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;35 kg: 250 mg once daily for 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Onychomycosis",
"     </b>",
"     (Gupta, 1997):  Limited data available: Children and Adolescents: Oral: Tablets:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     10-20 kg: 62.5 mg once daily for 6 weeks (fingernails) or 12 weeks (toenails)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     20-40 kg: 125 mg once daily for 6 weeks (fingernails) or 12 weeks (toenails)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;40 kg: 250 mg once daily for 6 weeks (fingernails) or 12 weeks (toenails)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"     <b>",
"      Onychomycosis:",
"     </b>",
"     Oral: Tablet: Fingernail: 250 mg once daily for 6 weeks; Toenail: 250 mg once daily for 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     No dosage adjustment provided in manufacturer&rsquo;s U.S. labeling; however, clearance is decreased 50% in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;50 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Hepatic cirrhosis: Use is not recommended in chronic or active hepatic disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F247741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LamISIL&reg;: 125 mg/packet (42s); 187.5 mg/packet (14s, 42s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LamISIL&reg;: 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Terbinex&trade;: 250 mg [kit includes Terbinex&trade; tablets (30s) and Eco-Formula&trade; nail enhancer]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Terbinex&trade;: 250 mg [kit includes Terbinex&trade; tablets (42s) and Eco-Formula&trade; nail enhancer]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9566193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10526801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets may be administered without regard to meals. Granules should be taken with food; sprinkle on a spoonful of nonacidic food (eg, pudding, mashed potatoes); do not use applesauce or fruit-based foods; swallow granules whole without chewing",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10526796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Granules: Store at controlled room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Store below 25&deg;C (77&deg;F); protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10526790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Granules: Treatment of tinea capitis (FDA approved in ages &ge;4 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Treatment of onychomycosis of the toenail or fingernail due to susceptible dermatophytes (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9566184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Terbinafine may be confused with terbutaline",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       LamISIL&reg; may be confused with LaMICtal&reg;, Lomotil&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9567972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Adverse events listed for tablets unless otherwise specified. Granules were studied in patients 4-12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever (granules), headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, nausea, taste disturbance, toothache (granules), vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver enzyme abnormalities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough (granules), nasal congestion (granules), nasopharyngitis (granules), pharyngeal pain (granules), rhinorrhea (granules), upper respiratory tract infection (children, granules)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Influenza (granules)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Angioedema, agranulocytosis, allergic reactions, alopecia, anaphylaxis, depression, generalized exanthematous pustulosis (acute), hepatic failure, neutropenia (severe), pancreatitis (acute), pancytopenia, precipitation/exacerbation of cutaneous and systemic lupus erythematosus, psoriasis exacerbation, rhabdomyolysis, smell disturbance (including loss of smell), Stevens-Johnson syndrome, thrombocytopenia, tinnitus, toxic epidermal necrolysis, vasculitis, vertigo, visual field acuity decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10526791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to terbinafine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10526793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients sensitive to allylamine antifungals (eg, naftifine, butenafine); cross-sensitivity to terbinafine may exist. Use with caution in patients with lupus; precipitation or exacerbation of cutaneous or systemic lupus erythematosus has been observed; discontinue if signs and/or symptoms develop. Depression has been reported with use; instruct patients to report depressive symptoms/mood changes. Due to potential toxicity, confirmation of diagnostic testing of nail or skin specimens prior to treatment of onychomycosis or dermatomycosis is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10526792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although rare, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported; discontinue therapy if progressive skin rash occurs. Transient decreases in absolute lymphocyte counts were observed in clinical trials; severe neutropenia (reversible upon discontinuation) has also been reported. Monitor CBC in patients with pre-existing immunosuppression if therapy is to continue &gt;6 weeks. Discontinue therapy if ANC &le;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Rare cases of hepatic failure (including fatal cases) have been reported; not recommended for use in patients with active or chronic liver disease including hepatic cirrohosis. Discontinue if symptoms or signs of hepatobiliary dysfunction or cholestatic hepatitis develop and assess hepatic function immediately. Not recommended for use in patients with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;50 mL/minute); clearance is reduced by approximately 50%.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Taste disturbance (including loss of taste) may occur and and severe cases resulting in weight loss or depression have been reported; resolution may be delayed (eg, several weeks to &gt;1 year) following discontinuation of therapy or in some cases, disturbance may be permanent. Discontinue therapy in patients with symptoms of taste disturbance. Smell disturbance (including loss of smell) has been reported; resolution may be delayed (eg, &gt;1 year) following discontinuation of therapy or in some cases, disturbance may be permanent. Discontinue therapy in patients with symptoms of smell disturbance. Although rare, changes in the ocular lens and retina have been reported; discontinuation of therapy may be required.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some tablet formulations may contain lactose and should be avoided in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption syndromes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9567975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (strong);",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F247734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Terbinafine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.  Management: Tetrabenazine adult dose should be reduced by 50% when starting a strong CYP2D6 inhibitor.  Maximum tetrabenazine adult dose is 50 mg/day when used with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Terbinafine (Systemic) may decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F247736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F247747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Avoid use in pregnancy since treatment of onychomycosis is postponable.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10526802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     AST/ALT prior to initiation, repeat if used &gt;6 weeks; CBC",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10526797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Synthetic allylamine derivative which inhibits squalene epoxidase, a key enzyme in sterol biosynthesis in fungi. This results in a deficiency in ergosterol within the fungal cell wall and results in fungal cell death. Active against most strains of",
"     <i>",
"      Trichophyton mentagrophytes",
"     </i>",
"     ,",
"     <i>",
"      Trichophyton rubrum",
"     </i>",
"     ; may be effective for infections of",
"     <i>",
"      Microsporum gypsum",
"     </i>",
"     and",
"     <i>",
"      M. nanum",
"     </i>",
"     ,",
"     <i>",
"      Trichophyton verrucosum",
"     </i>",
"     ,",
"     <i>",
"      Epidermophyton floccosum",
"     </i>",
"     ,",
"     <i>",
"      Candida albicans",
"     </i>",
"     , and",
"     <i>",
"      Scopulariopsis brevicaulis",
"     </i>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10526798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Children and Adults: &gt;70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Distributed to sebum and skin predominantly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Plasma: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic predominantly via CYP1A2, 3A4, 2C8, 2C9, and 2C19 to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 36% to 64%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, terminal: 200-400 hours; very slow release of drug from skin and adipose tissues occurs; effective half-life: Children: 27-31 hours; Adults: ~36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: Children and Adults: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Children and Adults: 70% in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clearance: Children (14-68 kg): 15.6-26.7 L/hour",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10526803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/46/9957?source=see_link\">",
"      see \"Terbinafine (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new medication during therapy without consulting prescriber. Use exactly as directed. Finish all of the prescription even if symptoms appear resolved, may take several months for full treatment (inadequate treatment may result in reinfection). May cause altered taste (normal). Report unusual fatigue, persistent loss of appetite, nausea or vomiting, dark urine/pale stool, or other persistent adverse response.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10527084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients should not be considered therapeutic failures until they have been symptom-free for 2-4 weeks following a course of treatment; GI complaints usually subside with continued administration.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10806645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 25 mg/mL oral suspension may be made using tablets. Crush twenty 250 mg tablets and reduce to a fine powder. Add small amount of a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; and mix to a uniform paste; mix while adding the vehicle in geometric proportions to",
"     <b>",
"      almost",
"     </b>",
"     200 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 200 mL. Label \"shake well\" and \"refrigerate\". Stable 42 days.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abdel-Rahman SM and Nahata MC, &ldquo;Oral Terbinafine: A New Antifungal Agent,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1997, 31(4):445-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19526/abstract-text/9101008/pubmed\" id=\"9101008\" target=\"_blank\">",
"        9101008",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Abdel-Rahman SM, Herron J, Fallon-Friedlander S, et al, \"Pharmacokinetics of Terbinafine in Young Children Treated for Tinea Capitis,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2005, 24(10):886-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19526/abstract-text/16220086/pubmed\" id=\"16220086\" target=\"_blank\">",
"        16220086",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Amichai B and Grunwald MH, &ldquo;Adverse Drug Reactions of the New Oral Antifungal Agents - Terbinafine, Fluconazole, and Itraconazole,&rdquo;",
"      <i>",
"       Int J Dermatol",
"      </i>",
"      , 1998, 37(6):410-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19526/abstract-text/9646122/pubmed\" id=\"9646122\" target=\"_blank\">",
"        9646122",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Angello JT, Voytovich RM, and Jan SA, &ldquo;A Cost/Efficacy Analysis of Oral Antifungals Indicated for the Treatment of Onychomycosis: Griseofulvin, Itraconazole, and Terbinafine,&rdquo;",
"      <i>",
"       Am J Manag Care",
"      </i>",
"      , 1997, 3(3):443-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19526/abstract-text/10173095/pubmed\" id=\"10173095\" target=\"_blank\">",
"        10173095",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Backer M, De Vroey C, Lesaffre E, et al, &ldquo;Twelve Weeks of Continuous Oral Therapy for Toenail Onychomycosis Caused by Dermatophytes: A Double-Blind Comparative Trial of Terbinafine 250 mg/day Versus Itraconazole 200 mg/day,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 1998, 38(5 Pt 3):S57-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19526/abstract-text/9594939/pubmed\" id=\"9594939\" target=\"_blank\">",
"        9594939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dwyer CM, White MI, and Sinclair TS, &ldquo;Cholestatic Jaundice Due to Terbinafine,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 1997, 136(6):976-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19526/abstract-text/9217846/pubmed\" id=\"9217846\" target=\"_blank\">",
"        9217846",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedlander SF, Aly R, Krafchik B, et al, &ldquo;Terbinafine in the Treatment of",
"      <i>",
"       Trichophyton",
"      </i>",
"      Tinea Capitis: A Randomized, Double-Blind, Parallel-Group, Duration-Finding Study,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2002, 109(4):602-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19526/abstract-text/11927703/pubmed\" id=\"11927703\" target=\"_blank\">",
"        11927703",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta AK and Shear NH, &ldquo;Terbinafine: An Update,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 1997, 37(6):979-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19526/abstract-text/9418768/pubmed\" id=\"9418768\" target=\"_blank\">",
"        9418768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta AK, Sibbald RG, Knowles SR, et al, &ldquo;Terbinafine Therapy May Be Associated With the Development of Psoriasis De Novo or Its Exacerbation: Four Case Reports and a Review of Drug Induced Psoriasis,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 1997, 36(5 Part 2):858-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19526/abstract-text/9146568/pubmed\" id=\"9146568\" target=\"_blank\">",
"        9146568",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta AK, Sibbald RG, Lynde CW, et al, &ldquo;Onychomycosis in Children: Prevalence and Treatment Strategies,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 1997, 36(3 Pt 1):395-402.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19526/abstract-text/9091470/pubmed\" id=\"9091470\" target=\"_blank\">",
"        9091470",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jones TC, &ldquo;Overview of the Use of Terbinafine in Children,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 1995, 132(5):683-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19526/abstract-text/7772471/pubmed\" id=\"7772471\" target=\"_blank\">",
"        7772471",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trepanier EF and Amsden GW, &ldquo;Current Issues in Onychomycosis,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1998, 32(2):204-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19526/abstract-text/9496407/pubmed\" id=\"9496407\" target=\"_blank\">",
"        9496407",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vickers AE, Sinclair JR, Zollinger M, et al, \"Multiple Cytochrome P-450s Involved in the Metabolism of Terbinafine Suggest a Limited Potential for Drug-Drug Interactions,\"",
"      <i>",
"       Drug Metab Dispos",
"      </i>",
"      , 1999, 27(9):1029-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19526/abstract-text/10460803/pubmed\" id=\"10460803\" target=\"_blank\">",
"        10460803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15936 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_4_19526=[""].join("\n");
var outline_f19_4_19526=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9566188\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9480131\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526800\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247741\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9566193\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526801\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526796\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526790\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9566184\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9567972\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526791\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526793\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526792\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9567975\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247734\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247736\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247747\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526802\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526797\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526798\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526803\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527084\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10806645\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15936\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15936|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34358?source=related_link\">",
"      Terbinafine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/46/9957?source=related_link\">",
"      Terbinafine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/47/6900?source=related_link\">",
"      Terbinafine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/53/39763?source=related_link\">",
"      Terbinafine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/30/1507?source=related_link\">",
"      Terbinafine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_4_19527="Stress fractures of the tibia and fibula";
var content_f19_4_19527=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Stress fractures of the tibia and fibula",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/4/19527/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/4/19527/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/4/19527/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/4/19527/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/4/19527/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/4/19527/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/4/19527/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/4/19527/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress fractures of the tibia and fibula occur in many athletes, especially runners, and also in nonathletes who suddenly increase their activity level or have an underlying illness predisposing them to stress fractures. Many factors appear to contribute to the development of these fractures including changes in athletic training, specific anatomic traits, decreased bone density, and disease states [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss stress fractures of the tibia and fibula in adults. An overview of stress fractures and discussions of other specific fractures are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link\">",
"     \"Overview of stress fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33747?source=see_link\">",
"     \"Stress fractures of the metatarsal shaft\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY, RISK FACTORS, AND MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both tibial and fibular stress fractures occur most commonly among athletes who participate in activities that involve prolonged walking, running, or jumping. Although most common among runners, where the incidence may be as high as 15 percent, these injuries also occur among ballet dancers, soccer and basketball players, and military recruits [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=see_link\">",
"     \"Overview of running injuries of the lower extremity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link\">",
"     \"Overview of stress fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Research into the etiology of tibial and fibular stress fractures is limited; however, possible risk factors are of three types:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activity-related factors, including excessive training, poor footwear, and irregular terrain [",
"      <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/1,6\">",
"       1,6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Biomechanical factors, including inflexibility or weakness of the calf muscles [",
"      <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/1\">",
"       1",
"      </a>",
"      ], unequal leg-length [",
"      <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/7\">",
"       7",
"      </a>",
"      ], and flat (pes planus) or high-arched (pes cavus) feet [",
"      <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Metabolic factors, including demineralized bone due to hormonal or nutritional imbalances and specific disease states",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The underlying features shared by this diverse group of proposed risk factors is their propensity either to increase the loading and bending forces placed on the bone or to reduce the capacity of the bone to handle such forces [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link\">",
"     \"Overview of stress fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among military recruits, and to a lesser degree athletes, women experience an increased incidence of stress fracture, ranging up to 3.5 times the incidence among men [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/6\">",
"     6",
"    </a>",
"    ]. Although the reasons for this discrepancy remain unclear, possible causes include eating disorders, preactivity conditioning levels, endocrine factors, differences in bone density, and skeletal alignment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/10\">",
"     10",
"    </a>",
"    ]. Caucasians have twice the risk of African-Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link\">",
"     \"Overview of stress fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stress fractures secondary to weakened bone (ie, insufficiency fractures) occur most commonly among older women with osteoporosis, but they also affect younger amenorrheic women, patients with certain systemic diseases, such as diabetes mellitus and rheumatoid arthritis, as well as patients taking particular medications, such as long-term corticosteroid therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/25/6553?source=see_link\">",
"     \"Epidemiology and etiology of premenopausal osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link\">",
"     \"Overview of medical care in adults with diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although it bears far less weight than the tibia, the fibula is very closely bound to the tibia by membranous and ligamentous attachments and is therefore susceptible to strain from some of the same deforming forces that cause tibial stress fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RELEVANT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tibia is the major weight-bearing bone of the lower leg (",
"    <a class=\"graphic graphic_picture graphicRef54800 \" href=\"UTD.htm?41/14/42213\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65590 \" href=\"UTD.htm?26/45/27349\">",
"     picture 2",
"    </a>",
"    ). The proximal tibial plateau forms the lower surface of the knee joint. The tibial shaft bridges the distance to the distal tibia, which contributes the superior articular surface of the ankle joint at the tibiotalar articulation as well as the medial malleolus. Another key bony landmark is the tibial tuberosity, which sits several centimeters below the joint line and serves as the attachment site for the patellar tendon. Although the tibial shaft is the most common site for stress fractures, they may also occur at the tibial plateau and the medial malleolus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A strong fibrous structure, the interosseous membrane, connects the tibia and fibula along the length of the two bones. Proximally, this structure, reinforced by strong anterior and posterior ligaments, forms a synovial joint, the proximal tibiofibular articulation. Distally the interosseous membrane and three ligaments, the anterior, posterior, and transverse tibiofibular ligaments, stabilize the superior ankle joint. Another fibrous structure, the crural fascia, surrounds the bones and muscles of the lower leg.",
"   </p>",
"   <p>",
"    Fascial extensions and the interosseous membrane separate the muscles, nerves, and vessels of the lower leg into four distinct compartments. Three of these, the anterior, posterior, and deep posterior compartments, all border the tibia and can be compromised by tibial injury. The lateral compartment borders the fibula.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial symptoms in most athletes suggest medial tibial stress syndrome (MTSS), commonly referred to as \"shin splints.\" (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=see_link\">",
"     \"Overview of running injuries of the lower extremity\"",
"    </a>",
"    .). Typically, there is a gradual progression of activity-related pain. Eventually the pain worsens and may occur with rest. Occasionally, the patient experiences an abrupt increase in pain at the site of milder chronic symptoms indicating that a repeatedly stressed area of bone has finally fractured.",
"   </p>",
"   <p>",
"    Diagnosis of a tibial or fibular stress fracture is suggested by such a history in a patient with risk factors (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology, risk factors, and mechanism of injury'",
"    </a>",
"    above) and the following clinical findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pain localizes to one specific area",
"     </li>",
"     <li>",
"      Local swelling and discrete bone tenderness are present",
"     </li>",
"     <li>",
"      Pain increases with the impact from running or jumping",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An inability to hop on the symptomatic leg for 10 repetitions (positive hop test) without excessive pain is also suggestive of the diagnosis. In this setting, further testing for a stress fracture is indicated.",
"   </p>",
"   <p>",
"    The differential diagnosis includes posterior tibialis or soleus muscle strain, posterior tibialis tendinosis, periostitis, and compartment syndrome. Of these, compartment syndrome is the most dire diagnosis and must be ruled out by measurement of compartment pressures, if there is any significant clinical suspicion of its presence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26358?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of tibial fractures in adults\", section on 'Acute compartment syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirmation on initial plain x-rays occurs in less than 50 percent of tibial stress fractures. Periosteal elevation, cortical thickening, sclerosis, or a true fracture line are positive findings (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62977 \" href=\"UTD.htm?34/7/34942\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69856 \" href=\"UTD.htm?8/42/8878\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73240 \" href=\"UTD.htm?22/36/23118\">",
"     image 3",
"    </a>",
"    ). In patients who have an initially positive x-ray, follow-up radiographs are not necessary unless the patient fails to improve appropriately with treatment.",
"   </p>",
"   <p>",
"    In the majority of patients who do not have an initially positive x-ray, an experienced clinician may elect to treat presumptively as long as symptoms are in a low-risk area (eg, the medial posterior aspect of the tibial shaft) (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Indications for orthopedic consultation or referral'",
"    </a>",
"    below). An exception is an athlete or other patient who will be embarking on a vigorous rehabilitation program; in these cases, confirmation of the fracture is required by other means [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographs taken three to four weeks following diagnosis typically show the positive findings listed above, consistent with fracture healing. However, when confirmation is required sooner, studies such as magnetic resonance imaging (MRI), bone scan, or computed tomography (CT) can be used for diagnosis.",
"   </p>",
"   <p>",
"    MRI is becoming the preferred study in the evaluation of stress fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/13\">",
"     13",
"    </a>",
"    ]. With regard to tibial and fibular stress fractures, MRI may be particularly helpful because it helps to differentiate stress fracture from shin splints and has both high sensitivity and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/13\">",
"     13",
"    </a>",
"    ]. When intraarticular stress fracture is suspected, MRI better differentiates bone injury from ligament or cartilage injury. Cost and lack of access to MRI may lead some clinicians to reserve its use for possible high-risk stress fractures.",
"   </p>",
"   <p>",
"    The advantages and disadvantages of the various imaging methods are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of stress fractures\", section on 'Imaging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once radiographic studies confirm the diagnosis of stress fracture, the clinician rarely needs subsequent imaging. Radiographic healing lags behind clinical healing: both bone scan and MRI may remain positive for up to 12 months following the original injury. Additional imaging plays a role only when the patient fails to improve appropriately with treatment. Studies are then performed to determine if the fracture has extended or developed an area of nonunion. In this setting, CT better images the fracture line in long bones than does plain radiograph, bone scan, or MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ORTHOPEDIC CONSULTATION OR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experienced primary care physicians can manage most tibial stress fractures. Orthopedic referral is required for stress fractures of the anterior tibial cortex.",
"   </p>",
"   <p>",
"    The most difficult tibial stress fractures to treat involve the anterior cortex, the tension-bearing side of the bone. They account for approximately 5 percent of all tibial stress fractures. Healing is often prolonged, and controversy exists as to whether surgical intervention, bone grafting, or other approaches improve outcome. Therefore, these fractures should be referred to an orthopedist [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/3\">",
"     3",
"    </a>",
"    ]. A linear lucency along the anterior tibia on plain x-rays, referred to as the \"dreaded anterior black line,\" is the hallmark of this injury (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73240 \" href=\"UTD.htm?22/36/23118\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Stress fractures of the medial malleolus are at greater risk for delayed healing and nonunion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/14\">",
"     14",
"    </a>",
"    ]. They merit close clinical monitoring to be certain healing is progressing appropriately, and they should be referred if there is evidence of delayed healing or persistent pain. A follow-up CT scan may confirm nonunion when the clinical picture remains perplexing.",
"   </p>",
"   <p>",
"    Intraarticular stress fractures merit orthopedic consultation at a minimum.",
"   </p>",
"   <p>",
"    Immediate orthopedic referral should also be made if at any time during initial or follow-up treatment bone scan or MRI reveals a severe fracture, as determined by the appropriate radiologic grading system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of stress fractures\", section on 'Imaging studies'",
"    </a>",
"    .) Such imaging is generally obtained if symptoms are severe or patients fail to improve appropriately with conservative management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment consists of rest and immobilization. For fractures at greater risk for delayed healing or nonunion, but which are still frequently managed by primary care physicians (eg, those of the tibial plateau and medial malleolus), treatment can include a short period of non-weight-bearing and immobilization in a long air splint, knee splint, or hinged brace. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Indications for orthopedic consultation or referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Tibial stress fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standard follow-up schedule for tibial shaft stress fractures. Follow-up is adjusted according to clinician judgment, patient symptoms, and response to treatment. Patients with injuries at relatively high-risk sites are seen more frequently. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Indications for orthopedic consultation or referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Design and implementation of an appropriate rehabilitation program is fundamental to follow-up care. Clinicians may wish to manage rehabilitation themselves, or they may refer the patient to a physical therapist. Each rehabilitation program should be constructed to meet the needs of the patient based on an assessment of the following factors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cause of the injury (eg, excessive or improper training, poor technique, poor nutrition)",
"     </li>",
"     <li>",
"      Nature of the injury (eg, site of fracture)",
"     </li>",
"     <li>",
"      Symptoms and examination findings",
"     </li>",
"     <li>",
"      Preinjury activity level and patient goals for treatment",
"     </li>",
"     <li>",
"      Patient age, prior injuries, and comorbidities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A relatively aggressive rehabilitation protocol allows a quicker return to sport for uncomplicated, low-risk fractures of the middle and distal third of the shaft. For these fractures, a systematic review found that treatment with a long air splint, also called a long air cast, (",
"    <a class=\"graphic graphic_picture graphicRef57089 \" href=\"UTD.htm?23/14/23791\">",
"     picture 3",
"    </a>",
"    ) enables the patient to return to activity up to six weeks sooner than standard casting and other treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example of such a relatively aggressive approach, the following is an outline of our basic rehabilitation program for motivated running athletes with low-risk fractures and no complicating factors:",
"   </p>",
"   <p>",
"    For weeks one and two, the athlete concentrates on cross training:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Long air splint is worn continuously while standing during cross training",
"     </li>",
"     <li>",
"      Ice is applied to injury for 10 minutes daily; may repeat if swelling increases and after training sessions",
"     </li>",
"     <li>",
"      Calcium 1500 mg and vitamin D 400 international units supplementation",
"     </li>",
"     <li>",
"      45 minutes stationary cycle daily",
"     </li>",
"     <li>",
"      Heel raises, toe raises, and squats with weight every other day: 25 to 30 percent of body weight is used for three sets of 15 repetitions for each exercise",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During weeks three and four, weight-bearing exercise begins in the long air splint:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Every other day, run 400",
"      <span class=\"nowrap\">",
"       m/walk",
"      </span>",
"      400 m for eight laps on a soft track times three sessions",
"     </li>",
"     <li>",
"      Next three sessions, every other day, run 500",
"      <span class=\"nowrap\">",
"       m/walk",
"      </span>",
"      300 m then 600",
"      <span class=\"nowrap\">",
"       m/200",
"      </span>",
"      m then 700",
"      <span class=\"nowrap\">",
"       m/100",
"      </span>",
"      m for a total of eight laps",
"     </li>",
"     <li>",
"      45 minutes stationary cycle on alternate days",
"     </li>",
"     <li>",
"      Daily icing as above",
"     </li>",
"     <li>",
"      Daily weight exercises: same routine as described for weeks one and two",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During weeks five and six, basic training begins in the long air splint:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      45 minutes stationary cycling on alternate days",
"     </li>",
"     <li>",
"      Run two miles every other day for three sessions",
"     </li>",
"     <li>",
"      Run 2.5 miles every other day for four sessions",
"     </li>",
"     <li>",
"      Continue daily weight exercises",
"     </li>",
"     <li>",
"      Icing after activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Weeks seven and eight, begin the process of training without splint support,",
"    <strong>",
"     if tenderness is absent and hop test is negative",
"    </strong>",
"    (ie, 10 hops on injured leg without pain):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Begin running 2.5 miles every other day",
"     </li>",
"     <li>",
"      Run without splint on first day and with splint on second day; thereafter, alternate splint use every other day",
"     </li>",
"     <li>",
"      Continue other therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Weeks 9 to 12 mark the progressive return to full intensity training; if tolerating running without splint, start at 20 minutes a day:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increase run duration by five minutes after two workouts at each level",
"     </li>",
"     <li>",
"      Five runs per week during weeks 9 and 10",
"     </li>",
"     <li>",
"      Six runs per week during weeks 11 and 12",
"     </li>",
"     <li>",
"      When tolerating 40 continuous minutes without significant pain, resume training",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment protocol is modified as follows if the patient experiences any significant pain or there is evidence of delayed healing:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      If the patient has problems at any stage of rehabilitation, move back one level for an additional week and then try to advance",
"     </li>",
"     <li>",
"      Continue all training for the first 12 weeks on a soft, level surface; the softer the better",
"     </li>",
"     <li>",
"      Evaluate the patient in the office every two weeks for signs of healing or injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although our approach to treatment is consistent with the majority of clinicians and sports medicine literature, strengthening exercises should be used cautiously. Eccentric exercises and stretching may impair fracture healing, if performed prematurely or too vigorously. The total time and intensity of weight-bearing must also progress gradually, so the injured bone has time to remodel and thereby increase its load-bearing capacity. Pain or persistent swelling indicates the bone requires additional rest before beginning active rehabilitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fibular stress fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A similar treatment approach is used with fibular stress fractures. Since most of these fractures occur in the distal third of the bone, use of a pneumatic leg brace similar to that used in studies of tibial stress fractures seems a reasonable treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/16\">",
"     16",
"    </a>",
"    ]. Most clinicians allow athletes to cross-train and use pain and limping as guidelines for when to reduce activity and when to allow resumption of regular training. For less serious fractures, brief runs on soft surfaces, while wearing an air stirrup, may be possible as early as one week after the initiation of treatment.",
"   </p>",
"   <p>",
"    We approach rehabilitation with a similar protocol to that described above for the tibia (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Tibial stress fractures'",
"    </a>",
"    above). Training progresses in a sequential fashion so as to maintain fitness without inhibiting fracture healing. Patients are generally able to resume training three to six weeks after the initiation of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Risk factor identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Part of good follow-up care is an assessment of risk factors that may have contributed to the development of the stress fracture. Biomechanical evaluation for such things as leg length discrepancy, calf muscle inflexibility, and flat or high-arched feet should be performed. Activity-related factors such as inadequate footwear, improper running surfaces, and inappropriate training regimens should be reviewed. Metabolic factors such as amenorrhea, poor nutrition, and osteoporosis should be investigated where appropriate. Referral to a physical therapist or nutritionist can be helpful. Details about specific risk factors and their modification are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=see_link\">",
"     \"Overview of running injuries of the lower extremity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link\">",
"     \"Overview of stress fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consideration of the female triad (eating disorder, amenorrhea, and osteoporosis) should be given to young women with stress fractures and a concerning history. Psychiatric referral may be needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36919?source=see_link\">",
"     \"Amenorrhea and infertility associated with exercise\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR RETURN TO WORK AND SPORTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The protocol described above (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Follow-up care'",
"    </a>",
"    above) serves as a template for the approach used in different sports. The key principle of protected, progressive exercise allows adequate bone healing while maintaining some degree of fitness, and it should be followed regardless of the sport.",
"   </p>",
"   <p>",
"    Occupational demands require careful consideration. Patients with physically demanding work should likely rest until healing is nearly complete. Patients with less physically demanding jobs can often return to work with an air splint after only a week or two of treatment, while those with sedentary jobs may be able to return to work immediately.",
"   </p>",
"   <p>",
"    Tibial fractures sometimes heal rapidly, and some athletes begin full training as early as eight weeks after their injury. Typically, by 12 weeks most uncomplicated fractures are sufficiently healed to allow for full training. Slower progress is expected in complicated fractures, such as those of the proximal tibia, tibial plateau, anterior tibial shaft, or medial malleolus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     UNIQUE PEDIATRIC CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric overuse injuries are thought to be increasing in frequency, and this includes stress fractures of both the tibia and fibula. Most authors attribute this trend to specialization in sports at earlier ages as well as more year round training programs that involve younger athletes who are skeletally immature. The frequency of stress fracture increases with age so that only 9 percent occur at ages 15 or less, with 32 percent in 16 to 19 year olds and 59 percent in patients over 20 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/17\">",
"     17",
"    </a>",
"    ]. While older adolescents (16 to 19 years of age) have greater bone maturity and their fracture pattern more closely resembles that of adults, stress fractures in younger children differ in presentation, location, and healing time.",
"   </p>",
"   <p>",
"    Retrospective observational studies suggest that the tibia is the most commonly affected bone in children followed by the fibula [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. In contrast to adults, the proximal tibia is the typical location, and midshaft anterior tibial stress fractures are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in adults, pediatric fibular stress fractures tend to occur distally. Proximal fibular stress fractures are uncommon and may arise from higher impact forces associated with jumping, although the precise mechanism remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately half of pediatric stress fractures are attributable to athletics. A significant number also occur in children with underlying osteopenia (eg, patients with congenital bone dysplasia, osteopenia from corticosteroid use and other chronic diseases associated with immobilization and weakness such as cerebral palsy), and these can evolve from sports, other recreational exercise, or normal daily activity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings of pediatric stress fracture are often subtle. Children may limp with minimal pain or may have a localized area of pain with activity that on examination is sensitive to touch, percussion, or vibration. Swelling at the site or inability to ambulate are less common.",
"   </p>",
"   <p>",
"    Plain radiographs of the affected area, including AP, lateral, and oblique views, are of greater diagnostic utility in children because of their rapid healing phase that promotes active new bone formation, periosteal thickening, and early callus. These findings are seen earlier and in more regions of bone than in adults.",
"   </p>",
"   <p>",
"    If plain radiographs are not diagnostic or are concerning for other pathology such as malignancy or osteomyelitis, then magnetic resonance imaging is the best confirmatory study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with stress fractures should have limitation of activity and immobilization with pneumatic braces, lower leg appliances, or casting. Healing time averages five weeks for pediatric tibial stress fractures and four weeks for distal fibular stress fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19527/abstract/18\">",
"     18",
"    </a>",
"    ]. Orthopedic referral is indicated in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Children with anterior tibial stress fractures",
"     </li>",
"     <li>",
"      Patients who fail to respond to typical care within six to eight weeks",
"     </li>",
"     <li>",
"      Patients for whom the diagnosis of stress fracture versus other bone abnormality is unclear",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Almost all children fully recover from their stress fracture with appropriate rest and immobilization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tibial and fibular stress fractures occur most commonly among runners and result from excessive training. Most tibial and fibular stress fractures respond well to cessation of the inciting activity and can be effectively managed by primary care physicians.",
"     </li>",
"     <li>",
"      Risk factors for tibial and fibular stress fractures are of three types: activity-related, biomechanical, and metabolic. Activity-related factors include poor footwear and irregular terrain. Biomechanical factors include inflexibility or weakness of the calf muscles, unequal leg-length, and flat (pes planus) or high-arched (pes cavus) feet. Metabolic factors include demineralized bone due to hormonal or nutritional imbalances and specific disease states. The underlying features shared by this diverse group of proposed risk factors are their propensity either to increase the loading and bending forces placed on the bone or to reduce the capacity of the bone to handle such forces. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology, risk factors, and mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptom onset from stress fractures of the tibia or fibula is usually insidious; pain is exacerbated by running or jumping. Generally, there is focal tenderness around the fracture site. Confirmation on initial plain x-rays occurs in less than 50 percent of tibial stress fractures. Bone scans and magnetic resonance imaging (MRI) are highly sensitive. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation and examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immediate orthopedic referral is needed for stress fractures of the anterior tibial cortex and severe fractures, as determined by bone scan or MRI grading. Referral is often made for intraarticular fractures, including those of the medial malleolus. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Indications for orthopedic consultation or referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The key principle of rehabilitation is protected, gradually progressive exercise that allows for adequate bone healing while maintaining some degree of fitness. Long air splints are recommended for immobilization during the initial weeks of healing and rehabilitation. Shock-absorbing insoles may reduce the risk of stress fracture. A detailed program is described above. Follow-up care should include assessment of risk factors that may have contributed to the development of the stress fracture. &nbsp;(see",
"      <a class=\"local\" href=\"#H8\">",
"       'Follow-up care'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Patients with physically demanding work should likely rest until healing is nearly complete. Patients with physically undemanding jobs can often return to work sooner while using an air splint. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Recommendations for return to work and sports'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Young adolescents and children with stress fractures have different patterns of injury, heal more quickly, and usually have excellent outcomes. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Unique pediatric considerations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19527/abstract/1\">",
"      Beck BR. Tibial stress injuries. An aetiological review for the purposes of guiding management. Sports Med 1998; 26:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19527/abstract/2\">",
"      Lundon, K, Melcher, L, Bray, K. Stress fractures in ballet: a twenty-five year review. J Dance Med Sci 1999; 3:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19527/abstract/3\">",
"      Hulkko, A, Alen, M, Orava, S. Stress fractures of the lower leg. Scand J Sports Sci 1987; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19527/abstract/4\">",
"      Matheson GO, Clement DB, McKenzie DC, et al. Stress fractures in athletes. A study of 320 cases. Am J Sports Med 1987; 15:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19527/abstract/5\">",
"      DiFiori JP. Stress fracture of the proximal fibula in a young soccer player: a case report and a review of the literature. Med Sci Sports Exerc 1999; 31:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19527/abstract/6\">",
"      Bennell KL, Brukner PD. Epidemiology and site specificity of stress fractures. Clin Sports Med 1997; 16:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19527/abstract/7\">",
"      Friberg O. Leg length asymmetry in stress fractures. A clinical and radiological study. J Sports Med Phys Fitness 1982; 22:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19527/abstract/8\">",
"      Sullivan D, Warren RF, Pavlov H, Kelman G. Stress fractures in 51 runners. Clin Orthop Relat Res 1984; :188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19527/abstract/9\">",
"      Boden BP, Osbahr DC, Jimenez C. Low-risk stress fractures. Am J Sports Med 2001; 29:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19527/abstract/10\">",
"      Crossley K, Bennell KL, Wrigley T, Oakes BW. Ground reaction forces, bone characteristics, and tibial stress fracture in male runners. Med Sci Sports Exerc 1999; 31:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19527/abstract/11\">",
"      Niva MH, Kiuru MJ, Haataja R, Pihlajam&auml;ki HK. Bone stress injuries causing exercise-induced knee pain. Am J Sports Med 2006; 34:78.",
"     </a>",
"    </li>",
"    <li>",
"     O'Connor FG, Wilder R, Nirschl R. Textbook of Running Injuries, McGraw Hill, New York 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19527/abstract/13\">",
"      Gaeta M, Minutoli F, Scribano E, et al. CT and MR imaging findings in athletes with early tibial stress injuries: comparison with bone scintigraphy findings and emphasis on cortical abnormalities. Radiology 2005; 235:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19527/abstract/14\">",
"      Clare, DJ. Stress fractures of the ankle in the athlete. Oper Tech Sports Med 2001; 9:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19527/abstract/15\">",
"      Rome K, Handoll HH, Ashford R. Interventions for preventing and treating stress fractures and stress reactions of bone of the lower limbs in young adults. Cochrane Database Syst Rev 2005; :CD000450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19527/abstract/16\">",
"      Dickson TB Jr, Kichline PD. Functional management of stress fractures in female athletes using a pneumatic leg brace. Am J Sports Med 1987; 15:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19527/abstract/17\">",
"      Coady CM, Micheli LJ. Stress fractures in the pediatric athlete. Clin Sports Med 1997; 16:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19527/abstract/18\">",
"      Walker RN, Green NE, Spindler KP. Stress fractures in skeletally immature patients. J Pediatr Orthop 1996; 16:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19527/abstract/19\">",
"      de la Cuadra P, Albi&ntilde;ana J. Pediatric stress fractures. Int Orthop 2000; 24:47.",
"     </a>",
"    </li>",
"    <li>",
"     Yngve DA. Stress fractures in the pediatric athlete. In: The Pediatric Athlete, Sullivan JA, Grana WA.  (Eds), American Academy of Orthopedic Surgery, Park Ridge 1988.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 218 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-8B005171DA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_4_19527=[""].join("\n");
var outline_f19_4_19527=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY, RISK FACTORS, AND MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RELEVANT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION AND EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INDICATIONS FOR ORTHOPEDIC CONSULTATION OR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Tibial stress fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fibular stress fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Risk factor identification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RECOMMENDATIONS FOR RETURN TO WORK AND SPORTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      UNIQUE PEDIATRIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/218\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/218|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/7/34942\" title=\"diagnostic image 1\">",
"      Distal tibia stress fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/42/8878\" title=\"diagnostic image 2\">",
"      Periosteal thickening of tibial stress fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/36/23118\" title=\"diagnostic image 3\">",
"      Stress fracture of the anterior tibial cortex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/218|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/14/42213\" title=\"picture 1\">",
"      Anterior anatomy of tibia and fibula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/45/27349\" title=\"picture 2\">",
"      Lateral anatomy of tibia and fibula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/14/23791\" title=\"picture 3\">",
"      Air cushioned leg splint",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36919?source=related_link\">",
"      Amenorrhea and infertility associated with exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/25/6553?source=related_link\">",
"      Epidemiology and etiology of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=related_link\">",
"      Overview of running injuries of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=related_link\">",
"      Overview of stress fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26358?source=related_link\">",
"      Overview of tibial fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33747?source=related_link\">",
"      Stress fractures of the metatarsal shaft",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_4_19528="Tadalafil: Drug information";
var content_f19_4_19528=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tadalafil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/38/9829?source=see_link\">",
"    see \"Tadalafil: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F224586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adcirca&reg;;",
"     </li>",
"     <li>",
"      Cialis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adcirca&reg;;",
"     </li>",
"     <li>",
"      Cialis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F224603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Phosphodiesterase-5 Enzyme Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F224587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Benign prostatic hyperplasia (with or without concomitant erectile dysfunction) (Cialis&reg;):",
"     </b>",
"     Oral: 5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment with concomitant medications:",
"     </b>",
"     CYP3A4 inhibitors (strong): 2.5 mg once daily; maximum: 2.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Erectile dysfunction (Cialis&reg;):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      As-needed dosing:",
"     </i>",
"     10 mg (U.S. labeling) or 20 mg (Canadian labeling) at least 30 minutes prior to anticipated sexual activity (dosing range: 5-20 mg); to be given as one single dose and not given more than once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Erectile function may be improved for up to 36 hours following a single dose; adjust dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Once-daily dosing:",
"     </i>",
"     2.5 mg once daily (U.S. labeling) or 5 mg once daily  (Canadian labeling) to be given at approximately the same time daily without regard to timing of sexual activity. Dose may be adjusted based on tolerability (dosage range:  2.5-5 mg/day).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment with concomitant medications:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     U.S. labeling: Alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers: If stabilized on either alpha-blockers or tadalafil therapy, initiate new therapy with the other agent at the lowest possible dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Canadian labeling: Nonselective alpha-blockers (eg, doxazosin):",
"     <i>",
"      As-needed dosing:",
"     </i>",
"     10 mg at least 30 minutes prior to anticipated sexual activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     CYP3A4 inhibitors (strong):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      As-needed dosing:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     U.S. labeling: Maximum: 10 mg, not to be given more frequently than every 72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Canadian labeling: 10 mg, not to be given more frequently than every 48 hours (maximum 3 doses/week); may increase to 20 mg if lower dose is tolerated but ineffective. Discontinue use if 10 mg dose is not tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Once-daily dosing:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     U.S. labeling: 2.5 mg once daily; maximum: 2.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Canadian labeling: 2.5-5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Pulmonary arterial hypertension (Adcirca&reg;):",
"     </b>",
"     Oral: 40 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment with concomitant medications:",
"     </b>",
"     <i>",
"      Coadministration with protease inhibitor regimen:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Concurrent use with atazanavir/ritonavir, darunavir/ritonavir, fosamprenavir, ritonavir, saquinavir/ritonavir, tipranavir/ritonavir:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Coadministration of tadalafil in patients currently receiving one of these protease inhibitor regimens for at least 1 week: Initiate tadalafil at 20 mg once daily; increase to 40 mg once daily based on individual tolerability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Coadministration of  one of these protease inhibitor regimens in patients currently receiving tadalafil: Discontinue tadalafil at least 24 hours prior to the initiation of the protease inhibitor regimen. After at least 1 week of the protease inhibitor regimen, resume tadalafil at 20 mg once daily; increase to 40 mg once daily based on individual tolerability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Concurrent use with indinavir or nelfinavir:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Patient receiving indinavir/nelfinavir when initiating tadalafil: Initiate tadalafil at 20 mg once daily; increase to 40 mg once daily based on individual tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Patient receiving tadalafil when initiating indinavir/nelfinavir: Adjust tadalafil to 20 mg once daily; increase to 40 mg once daily based on individual tolerability",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F224588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. No dose adjustment for patients &gt;65 years of age in the absence of renal or hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F224589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Benign prostatic hyperplasia (with or without concomitant erectile dysfunction) (Cialis&reg;):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;51 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: Initial: 2.5 mg once daily; maximum: 5 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ESRD requiring hemodialysis: Use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Erectile dysfunction (Cialis&reg;):",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      As-needed use:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     U.S. labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;51 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: Initial: 5 mg once daily; maximum: 10 mg (not to be given more frequently than every 48 hours).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Maximum: 5 mg (not to be given more frequently than every 72 hours).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ESRD requiring hemodialysis: Maximum: 5 mg (not to be given more frequently than every 72 hours).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;80 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;31-80 mL/minute: 10 mg, not to be given more frequently than every 48 hours (maximum: 3 doses/week); may increase to 20 mg if lower dose is tolerated but ineffective. Discontinue use if 10 mg dose is not tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use with extreme caution; has not been adequately studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ESRD requiring hemodialysis: Use with extreme caution; has not been adequately studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Once-daily use:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;31 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ESRD requiring hemodialysis: Use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Pulmonary arterial hypertension (Adcirca&reg;):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;80 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-80 mL/minute: Initial: 20 mg once daily; increase to 40 mg once daily based on individual tolerability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Avoid use due to increased tadalafil exposure, limited clinical experience, and lack of ability to influence clearance by dialysis.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F224590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Benign prostatic hyperplasia (with or without concomitant erectile dysfunction) (Cialis&reg;):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-to-moderate hepatic impairment (Child-Pugh class A or B): Use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe hepatic impairment (Child-Pugh class C): Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Erectile dysfunction (Cialis&reg;):",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      As-needed use:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     U.S. labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild-to-moderate impairment (Child-Pugh class A or B): Use with caution; dose should not exceed 10 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe impairment (Child-Pugh class C): Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild-to-moderate impairment (Child-Pugh class A or B): 10 mg, not to be given more frequently than every 48 hours (maximum: 3 doses/week); may increase to 20 mg if lower dose is tolerated but ineffective. Discontinue use if 10 mg dose is not tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe impairment (Child-Pugh class C): Use with extreme caution; has not been adequately studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Once-daily use:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     U.S. labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild-to-moderate impairment (Child-Pugh class A or B): Use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe impairment (Child-Pugh class C): Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild-to-moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe impairment (Child-Pugh class C): Use with extreme caution; has not been adequately studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Pulmonary arterial hypertension (Adcirca&reg;):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-to-moderate hepatic impairment (Child-Pugh class A or B): Use with caution; consider initial dose of 20 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe hepatic impairment (Child-Pugh class C): Avoid use; has not been studied in patients with severe hepatic cirrhosis.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F224562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adcirca&reg;: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cialis&reg;: 2.5 mg, 5 mg, 10 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F224549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F224565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adcirca&reg;: Administer daily dose all at once; dividing doses throughout the day is not advised.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cialis&reg;: When used on an as-needed basis, should be taken at least 30 minutes prior to sexual activity. When used on a once-daily basis, should be taken at the same time each day, without regard to timing of sexual activity.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F224564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adcirca&reg;: Treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cialis&reg;: Treatment of erectile dysfunction (ED); treatment of signs and symptoms of benign prostatic hyperplasia (BPH)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6472503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tadalafil may be confused with sildenafil, vardenafil",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Adcirca&reg; may be confused with Advair&reg; Diskus&reg;, Advair&reg; HFA, Advicor&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F224601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Based upon usual doses for either indication. For erectile dysfunction, similar adverse events are reported with once-daily versus intermittent dosing, but are generally lower than with doses used intermittently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing (1% to 13%; dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (3% to 42%; dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (1% to 13%), nausea (10% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (1% to 14%; dose related), back pain (2% to 12%), extremity pain (1% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory tract infection (3% to 13%), nasopharyngitis (2% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Gastroenteritis (viral; 3% to 5%), GERD (1% to 3%), abdominal pain (1% to 2%), diarrhea (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasal congestion (&le;9%), cough (2% to 4%), bronchitis (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Amnesia (transient global), angina pectoris, arthralgia, blurred vision, chest pain, color vision decreased, conjunctival hyperemia, conjunctivitis, diaphoresis, dizziness, dysphagia, dyspnea, epistaxis, esophagitis, exfoliative dermatitis, eye pain, eyelid swelling, facial edema, fatigue, gastritis, GGTP increased, hearing decreased, hearing loss, hepatic enzymes increased, hypoesthesia, hypotension, insomnia, lacrimation, migraine, MI, neck pain, nonarteritic ischemic optic neuropathy (NAION), orthostatic hypotension, pain, palpitation, paresthesia, pharyngitis, priapism, pruritus, rash, retinal artery occlusion, retinal vein occlusion, seizure, somnolence, spontaneous penile erection, Stevens-Johnson syndrome, stroke, sudden cardiac death, syncope, tachycardia, tinnitus, urticaria, vertigo, visual field loss, vomiting, weakness, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F224568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Known serious hypersensitivity to tadalafil or any component of the formulation; concurrent use (regularly/intermittently) of organic nitrates in any form (eg, nitroglycerin, isosorbide dinitrate)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F224552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anginal chest pain: Patients experiencing anginal chest pain after tadalafil administration should seek immediate medical attention (also see \"Concurrent drug therapy issues\").",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Color discrimination: May cause dose-related impairment of color discrimination. Use caution in patients with retinitis pigmentosa; a minority have genetic disorders of retinal phosphodiesterases (no safety information available).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hearing loss: Sudden decrease or loss of hearing has been reported rarely; hearing changes may be accompanied by tinnitus and dizziness. Instruct patients to seek medical assistance for sudden decrease in hearing or loss of hearing.  A direct relationship between therapy and hearing loss has not been determined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Decreases in blood pressure may occur due to vasodilator effects; use with caution in patients with left ventricular outflow obstruction (aortic stenosis or hypertrophic obstructive cardiomyopathy); may be more sensitive to hypotensive actions. Concurrent use with alpha-adrenergic antagonist therapy may cause symptomatic hypotension; patients should be hemodynamically stable prior to initiating therapy at the lowest possible dose. Avoid or limit concurrent substantial ethanol  consumption as this may increase the risk of symptomatic hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Priapism: Painful erection &gt;6 hours in duration; rare. Instruct patient to seek medical assistance for erection lasting &gt;4 hours. Use with caution in patients who have conditions which may predispose them to priapism (eg, sickle cell anemia, multiple myeloma, leukemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vision loss: Vision loss (rare) may be a sign of nonarteritic anterior ischemic optic neuropathy (NAION). Instruct patients to seek medical assistance for sudden loss of vision in one or both eyes. Risk may be increased with history of vision loss or NAION in one eye. Other risk factors for NAION include low cup-to-disc ratio (\"crowded disc\"), coronary artery disease, diabetes, hypertension, hyperlipidemia, smoking, and &gt;50 years of age. Safety has not been evaluated in patients with known degenerative retinal disorders (eg, retinitis pigmentosa); use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anatomical penis deformation: Use with caution in patients with anatomical deformation of the penis (angulation, cavernosal fibrosis, or Peyronie's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with bleeding disorders; safety and efficacy have  not been established.",
"     <i>",
"      In vitro",
"     </i>",
"     studies have suggested a decreased effect on platelet aggregation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use is not recommended in patients with hypotension (&lt;90/50 mm Hg), uncontrolled hypertension (&gt;170/100 mm Hg), NYHA class II-IV heart failure within the last 6 months, uncontrolled arrhythmias, stroke within the last 6 months, MI within the last 3 months, unstable angina or angina during sexual intercourse; safety and efficacy have not been evaluated in these patients. Safety and efficacy in PAH have not been evaluated in patients with clinically significant aortic and/or mitral valve disease, life-threatening arrhythmias, hypotension (&lt;90/50 mm Hg), uncontrolled hypertension, significant left ventricular dysfunction, pericardial constriction, restrictive or congestive cardiomyopathy, symptomatic coronary artery disease. Use caution in patients with left ventricular outflow obstruction (eg, aortic stenosis, hypertrophic obstructive cardiomyopathy); may be more sensitive to vasodilator effects. There is a degree of cardiac risk associated with sexual activity; therefore, physicians may wish to consider the cardiovascular status of their patients prior to initiating any treatment for erectile dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild-to-moderate hepatic impairment; dosage adjustment/limitation is needed. Use is not recommended in patients with severe hepatic impairment or cirrhosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peptic ulcer disease: Use with caution in patients with active peptic ulcer disease due to effect on platelets (bleeding); safety and efficacy have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary veno-occlusive disease (PVOD): Pulmonary vasodilators may exacerbate the cardiovascular status in patients with PVOD. Use is not recommended; no clinical data exists in patients with PVOD. In patients with unrecognized PVOD, signs of pulmonary edema should prompt investigation into this diagnosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment/limitation is needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Alpha-blockers: When used for erectile dysfunction, use with caution in patients taking alpha-blockers; may cause hypotension. Safety of this combination may be affected by other antihypertensives and intravascular volume depletion. Patients should be hemodynamically stable prior to initiating therapy. Initiate tadalafil at the lowest recommended dose. Alpha-blockers should be initiated at the lowest recommended dose in patients currently taking tadalafil. When used for treatment of BPH, concomitant use with alpha-blockers is not recommended; discontinue alpha-blocker at least 1 day before initiating tadalafil.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions:",
"     <i>",
"      BPH/Erectile dysfunction:",
"     </i>",
"     Use with caution in patients taking strong CYP3A4 inhibitors (see Drug Interactions); consider alternative agents that avoid or lessen the potential for CYP-mediated interactions. Once-daily tadalafil dosing results in continuous plasma levels; use caution when administered concurrently with these medications.",
"     <i>",
"      PAH:",
"     </i>",
"     Avoid use in patients taking strong CYP3A4 inducers/inhibitors. Use in patients receiving or about to receive ritonavir requires dosage adjustment or interruption of therapy, respectively. Canadian labeling does not recommend use of tadalafil in patients with PAH who are also receiving protease inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nitrates: Concomitant use (regularly/intermittently) with all forms of nitrates is contraindicated. Nitrate-mediated vasodilation is markedly exaggerated and prolonged in the presence of PDE-5 inhibitors. When tadalafil is used for BPH, erectile dysfunction, or PAH and nitrate administration is medically necessary (eg, chest pain refractory to other treatments) following the use of tadalafil, at least 48 hours should elapse after the tadalafil dose and nitrate administration. When used for PAH, per the manufacturer, nitrate may be administered within 48 hours of tadalafil. For both situations, administration of nitrates should only be done under close medical supervision with hemodynamic monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Other phosphodiesterase-5 (PDE-5) inhibitors: Safety and efficacy with other tadalafil brands or other PDE-5 inhibitors (ie, sildenafil and vardenafil) have not been established. Patients should be informed not to take with other tadalafil brands or other PDE-5 inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Other treatments for erectile dysfunction: Safety and efficacy with other treatments for erectile dysfunction have not been established; use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Potential underlying causes of erectile dysfunction or BPH should be evaluated prior to treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F224597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F224556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Alpha1-Blockers.  Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alprostadil: Phosphodiesterase 5 Inhibitors may enhance the adverse/toxic effect of Alprostadil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amyl Nitrite: Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Amyl Nitrite.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: Phosphodiesterase 5 Inhibitors may enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Tadalafil. Management: Avoid tadalafil when used for treatment of pulmonary arterial hypertension in patients receiving boceprevir.  Tadalafil for erectile dysfunction should be limited to 10 mg every 72 hours with close monitoring for tadalafil toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Phosphodiesterase 5 Inhibitors may increase the serum concentration of Bosentan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Tadalafil. Management: Recommendations regarding use of tadalafil in patients also receiving the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate product vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Tadalafil. Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Tadalafil. Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Management: No empiric dosage adjustments are recommended with concomitant therapy; however, dose of the phosphodiesterase inhibitor may need to be altered based on clinical response.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Tadalafil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Tadalafil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Tadalafil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lorcaserin: May enhance the adverse/toxic effect of Phosphodiesterase 5 Inhibitors. Specifically, the risk of developing priapism may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the adverse/toxic effect of other Phosphodiesterase 5 Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Tadalafil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of Tadalafil. Management: Recommendations regarding use of tadalafil in patients also receiving ritonavir may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sapropterin: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Tadalafil. Management: Concurrent use of tadalafil for treatment of pulmonary arterial hypertension is contraindicated with telaprevir.  Tadalafil for erectile dysfunction should be limited to 10 mg per 72 hours, with close monitoring for tadalafil toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vasodilators (Organic Nitrates): Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Vasodilators (Organic Nitrates).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Tadalafil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F224583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">",
"     Ethanol: Substantial consumption of ethanol may increase the risk of hypotension and orthostasis. Lower ethanol consumption has not been associated with significant changes in blood pressure or increase in orthostatic symptoms. Management: Avoid or limit ethanol consumption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Rate and extent of absorption are not affected by food. Grapefruit juice may increase serum levels/toxicity of tadalafil. Management: Use of grapefruit juice should be limited or avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease the levels/effectiveness of tadalafil. Management: Avoid or use caution with concomitant use.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F224558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F224571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic events were not reported in animal reproduction studies. Postnatal development and pup survival was decreased at some doses. There are no adequate and well-controlled studies in pregnant women. Less than 0.0005% is found in the semen of healthy males.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5717046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F224572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F224570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Adcirca Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (60): $1909.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cialis Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (15): $74.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (30): $148.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $954.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $954.72",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F224560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, response and adverse effects; urine flow, PSA",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F224573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      36 Horas (PY);",
"     </li>",
"     <li>",
"      Adcirca (AT, CZ, DK, EE, FR, GB, IE, NO, PT, SE);",
"     </li>",
"     <li>",
"      Cialis (AR, AT, AU, BB, BE, BF, BG, BJ, BR, BS, CH, CI, CL, CN, CO, CR, CZ, DE, DK, DO, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, ID, IE, IL, IT, JM, KE, KP, LR, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, PA, PE, PH, PL, PT, RU, SC, SD, SE, SG, SK, SL, SN, SV, TH, TN, TR, TT, TW, TZ, UG, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Forzest (IN);",
"     </li>",
"     <li>",
"      Pasport (TR);",
"     </li>",
"     <li>",
"      Xpandyl (GT);",
"     </li>",
"     <li>",
"      Zydalis (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F224551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BPH: Exact mechanism unknown; effects likely due to PDE-5 mediated reduction in smooth muscle and endothelial cell proliferation, decreased nerve activity, and increased smooth muscle relaxation and tissue perfusion of the prostate and bladder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erectile dysfunction: Does not directly cause penile erections, but affects the response to sexual stimulation. The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation and inflow of blood to the corpus cavernosum. Tadalafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE-5), which is responsible for degradation of cGMP in the corpus cavernosum; when sexual stimulation causes local release of NO, inhibition of PDE-5 by tadalafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum. At recommended doses, it has no effect in the absence of sexual stimulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PAH: Inhibits phosphodiesterase type 5 (PDE-5) in smooth muscle of pulmonary vasculature where PDE-5 is responsible for the degradation of cyclic guanosine monophosphate (cGMP). Increased cGMP concentration results in pulmonary vasculature relaxation; vasodilation in the pulmonary bed and the systemic circulation (to a lesser degree) may occur.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F224567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect (pulmonary artery vasodilation): 75-90 minutes (Ghofrani, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Erectile dysfunction: Up to 36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 63-77 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 94%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, via CYP3A4 to metabolites (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 15-17.5 hours; Pulmonary hypertension (not receiving bosentan): 35 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: ~2-4 hours (range: 30 minutes to 8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~61%, predominantly as metabolites); urine (~36%, predominantly as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Andersson KE, de Groat WC, McVary KT, et al, \"Tadalafil for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Pathophysiology and Mechanism(s) of Action,\"",
"      <i>",
"       Neurourol Urodyn",
"      </i>",
"      , 2011, 30(3):292-301.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, \"2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(18):e426-579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19528/abstract-text/21444888/pubmed\" id=\"21444888\" target=\"_blank\">",
"        21444888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe DT, Armstrong PW, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(9):e82-292.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19528/abstract-text/15339869/pubmed\" id=\"15339869\" target=\"_blank\">",
"        15339869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheitlin MD, Hutter AM Jr, Brindis RG, et al, &ldquo;Use of Sildenafil (Viagra&reg;) in Patients With Cardiovascular Disease,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(1):273-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19528/abstract-text/9935041/pubmed\" id=\"9935041\" target=\"_blank\">",
"        9935041",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Curran M and Keating G, &ldquo;Tadalafil,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2003, 63(20):2203-12; discussion 2213-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19528/abstract-text/14498756/pubmed\" id=\"14498756\" target=\"_blank\">",
"        14498756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daugan A, Grondin P, Ruault C, et al, &ldquo;The Discovery of Tadalafil: A Novel and Highly Selective PDE-5 Inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1&prime;,2&prime;:1,6]pyrido[3,4-b]indole-1,4-dione Analogues,&rdquo;",
"      <i>",
"       J Med Chem",
"      </i>",
"      , 2003, 46(21):4533-42.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fraunfelder FW,  &ldquo;Visual Side Effects Associated With Erectile Dysfunction Agents,&rdquo;",
"      <i>",
"       Am J Ophthal",
"      </i>",
"      , 2005, 140 (4):723-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19528/abstract-text/16226525/pubmed\" id=\"16226525\" target=\"_blank\">",
"        16226525",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Galie N, Brundage BH, Ghofrani HA, et al, &ldquo;Tadalafil Therapy for Pulmonary Arterial Hypertenstion,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2009, 119(22):2894-903.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19528/abstract-text/19470885/pubmed\" id=\"19470885\" target=\"_blank\">",
"        19470885",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghofrani HA, Voswinckel R, Reichenberger F, et al, &ldquo;Differences in Hemodynamic and Oxygenation Responses to Three Different Phosphodiesterase-5 Inhibitors in Patients with Pulmonary Arterial Hypertension,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2004, 44(7):1488-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19528/abstract-text/15464333/pubmed\" id=\"15464333\" target=\"_blank\">",
"        15464333",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jackson G, Rosen RC, Kloner RA, et al, &ldquo;The Second Princeton Consensus on Sexual Dysfunction and Cardiac Risk: New Guidelines for Sexual Medicine,&rdquo;",
"      <i>",
"       J Sex Med",
"      </i>",
"      , 2006, 3(1):28-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19528/abstract-text/16409215/pubmed\" id=\"16409215\" target=\"_blank\">",
"        16409215",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kloner RA, Mitchell M, and Emmick JT, &ldquo;Cardiovascular Effects of Tadalafil,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 2003, 92(9A):37M-46M.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19528/abstract-text/14609622/pubmed\" id=\"14609622\" target=\"_blank\">",
"        14609622",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kloner RA, Mitchell M, and Emmick JT, &ldquo;Cardiovascular Effects of Tadalafil in Patients on Common Antihypertensive Therapies,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 2003, 92(9A):47M-57M.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19528/abstract-text/14609623/pubmed\" id=\"14609623\" target=\"_blank\">",
"        14609623",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McLaughlin VV, Archer SL, Badesch DB, et al, &ldquo;ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(17):1573&ndash;619.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19528/abstract-text/19389575/pubmed\" id=\"19389575\" target=\"_blank\">",
"        19389575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McVary KT, &ldquo;Clinical Practice. Erectile Dysfunction,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(24):2472-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19528/abstract-text/18077811/pubmed\" id=\"18077811\" target=\"_blank\">",
"        18077811",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Padma-Nathan H, &ldquo;Efficacy and Tolerability of Tadalafil, A Novel Phosphodiesterase 5 Inhibitor, in Treatment of Erectile Dysfunction,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 2003, 92(9A):19-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19528/abstract-text/14609620/pubmed\" id=\"14609620\" target=\"_blank\">",
"        14609620",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10108 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-B6FAD70B64-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_4_19528=[""].join("\n");
var outline_f19_4_19528=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224586\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854896\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224603\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224587\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224588\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224589\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224590\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224562\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224549\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224565\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224564\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6472503\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224601\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224568\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224552\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224597\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224556\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224583\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224558\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224571\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5717046\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224572\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224570\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224560\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224573\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224551\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224567\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10108\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10108|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/38/9829?source=related_link\">",
"      Tadalafil: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_4_19529="Amlodipine and atorvastatin: Drug information";
var content_f19_4_19529=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amlodipine and atorvastatin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/8/22661?source=see_link\">",
"    see \"Amlodipine and atorvastatin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F134133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Caduet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2935689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Caduet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F134151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antianginal Agent;",
"     </li>",
"     <li>",
"      Antilipemic Agent, HMG-CoA Reductase Inhibitor;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker, Dihydropyridine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F134134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose is individualized; combination product may be used as initial therapy or substituted for individual components in patients currently maintained on both agents separately or in patients not adequately controlled with monotherapy (using one of the agents or an agent within same pharmacologic class).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension, angina, and hyperlipidemia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial therapy: Amlodipine 5 mg  and atorvastatin 10-20 mg once daily; dose may be titrated after 1-2 weeks (amlodipine component) and after 2-4 weeks (atorvastatin component) to a maximum daily dose: Amlodipine 10 mg; atorvastatin 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Add-on therapy/replacement therapy: Amlodipine 5-10 mg  and atorvastatin 10-80 mg once daily; dose may be titrated after 1-2 weeks (amlodipine component) and after 2-4 weeks (atorvastatin component) to a maximum daily dose: Amlodipine 10 mg; atorvastatin 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for atorvastatin with concomitant medications:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Boceprevir, nelfinavir:",
"     </i>",
"     Use lowest effective atorvastatin dose (not to exceed 40 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Clarithromycin, itraconazole, fosamprenavir, ritonavir (plus darunavir, fosamprenavir, or saquinavir):",
"     </i>",
"     Use lowest effective atorvastatin dose (not to exceed 20 mg daily)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F134145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose is individualized; combination product may be used as initial therapy or substituted for individual components in patients currently maintained on both agents separately or in patients not adequately controlled with monotherapy (using one of the agents or an agent within same pharmacologic class).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension and hyperlipidemia:",
"     </b>",
"     10-17 years (females &gt;1 year postmenarche): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial therapy: Amlodipine 2.5 mg  and atorvastatin 10 mg once daily; dose may be titrated after 1-2 weeks (amlodipine component) and after 2-4 weeks (atorvastatin component) to a maximum daily dose: Amlodipine 5 mg; atorvastatin 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Add-on therapy/replacement therapy: Amlodipine 2.5-5 mg  and atorvastatin 10-20 mg once daily; dose may be titrated after 1-2 weeks (amlodipine component) and after 2-4 weeks (atorvastatin component) to a maximum daily dose: Amlodipine 5 mg; atorvastatin 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Dosage adjustment for atorvastatin with concomitant medications:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2984004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing. Consider starting amlodipine at the lower end of dosing range due to increased incidence of hepatic, renal, or cardiac impairment. Elderly patients also show decreased clearance of amlodipine.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F134135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment is necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F134136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in patients with active liver disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F134118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral: Amlodipine 2.5 mg and atorvastatin 10 mg; Amlodipine 2.5 mg and atorvastatin 20 mg; Amlodipine 2.5 mg and atorvastatin 40 mg;  Amlodipine 5 mg and atorvastatin 10 mg; Amlodipine 5 mg and atorvastatin 20 mg; Amlodipine 5 mg and atorvastatin 40 mg; Amlodipine 5 mg and atorvastatin 80 mg; Amlodipine 10 mg and atorvastatin 10 mg; Amlodipine 10 mg and atorvastatin 20 mg; Amlodipine 10 mg and atorvastatin 40 mg; Amlodipine 10 mg and atorvastatin 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Caduet&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     2.5/10: Amlodipine 2.5 mg and atorvastatin 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     2.5/20: Amlodipine 2.5 mg and atorvastatin 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     2.5/40: Amlodipine 2.5 mg and atorvastatin 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     5/10: Amlodipine 5 mg and atorvastatin 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     5/20: Amlodipine 5 mg and atorvastatin 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     5/40: Amlodipine 5 mg and atorvastatin 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     5/80: Amlodipine 5 mg and atorvastatin 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     10/10: Amlodipine 10 mg and atorvastatin 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     10/20: Amlodipine 10 mg and atorvastatin 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     10/40: Amlodipine 10 mg and atorvastatin 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     10/80: Amlodipine 10 mg and atorvastatin 80 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F134106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F134121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F134120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For use when treatment with both amlodipine and atorvastatin is appropriate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Amlodipine:  Treatment of hypertension; treatment of chronic stable angina, vasospastic (Prinzmetal's) angina (confirmed or suspected); prevention of hospitalization or to decrease coronary revascularization procedure due to angina with documented CAD (limited to patients without heart failure or ejection fraction &lt;40%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Atorvastatin: Treatment of dyslipidemias or primary prevention of cardiovascular disease (atherosclerotic) as detailed here:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primary prevention of cardiovascular disease (high-risk for CVD): To reduce the risk of MI or stroke in patients without evidence of coronary heart disease who have multiple CVD risk factors or type 2 diabetes; also reduces the risk for angina or revascularization procedures in patients with multiple CVD risk factors without evidence of coronary heart disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Secondary prevention of cardiovascular disease: To reduce the risk of MI, stroke, revascularization procedures, angina, and hospitalization for heart failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of dyslipidemias: To reduce elevations in total cholesterol, LDL-C, apolipoprotein B, and triglycerides in patients with elevations of one or more components, and/or to increase low HDL-C as present in heterozygous familial/nonfamilial hypercholesterolemia and mixed dyslipidemia (Fredrickson type IIa and IIb hyperlipidemias); treatment of primary dysbetalipoproteinemia (Fredrickson type III), elevated serum TG levels (Fredrickson type IV), and homozygous familial hypercholesterolemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of heterozygous familial hypercholesterolemia (HeFH) in adolescent patients (10-17 years of age, females &gt;1 year postmenarche) having LDL-C &ge;190 mg/dL or LDL-C &ge;160 mg/dL with positive family history of premature cardiovascular disease (CVD) or with two or more CVD risk factors.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F134149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F134124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amlodipine, atorvastatin, or any component of the formulation; active liver disease; unexplained persistent elevations of serum transaminases; pregnancy; breast-feeding",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Telaprevir Canadian product monograph contraindicates use with atorvastatin.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F134108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angina/MI: Increased angina and/or MI has occurred with initiation or dosage titration of dihydropyridine calcium channel blockers. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease especially in the absence of concurrent beta-blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes mellitus: Increases in Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     and fasting blood glucose have been reported with HMG-CoA reductase inhibitors; however, the benefits of statin therapy far outweigh the risk of dysglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Postmarketing reports of fatal and nonfatal hepatic failure with atorvastatin are rare. If serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy. If an alternate etiology is not identified, do not restart atorvastatin. Liver enzyme tests should be obtained at baseline and as clinically indicated; routine periodic monitoring of liver enzymes is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur with amlodipine; blood pressure must be lowered at a rate appropriate for the patient's clinical condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune-mediated necrotizing myopathy (IMNM): IMNM, an autoimmune-mediated myopathy, has been reported (rarely) with HMG-CoA reductase inhibitor therapy.  IMNM presents as proximal muscle weakness with elevated CPK levels, which persists despite discontinuation of HMG-CoA reductase inhibitor therapy; additionally, muscle biopsy may show necrotizing myopathy with limited inflammation.  Immunosuppressive therapy (eg, corticosteroids, azathioprine) may be used for treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy/rhabdomyolysis: Patients receiving HMG-CoA reductase inhibitors have developed rhabdomyolysis with acute renal failure and/or myopathy; patients should be monitored closely. This risk is dose-related and is increased with concurrent use of CYP3A4 inhibitors (eg, clarithromycin, protease inhibitors), fibric acid derivatives (eg, gemfibrozil), or niacin (doses &ge;1 g/day) (see Drug Interactions). If concurrent use of clarithromycin or combination protease inhibitors (eg, lopinavir/ritonavir or ritonavir/saquinavir) is warranted consider dose adjustment of atorvastatin. Ensure patient is on the lowest effective atorvastatin dose in all circumstances. Discontinue in any patient in which CPK levels are markedly elevated (&gt;10 times ULN) or if myopathy is suspected/diagnosed. The manufacturer recommends temporary discontinuation for elective major surgery, acute medical or surgical conditions, or in any patient experiencing an acute or serious condition predisposing to renal failure (eg, sepsis, hypotension, trauma, uncontrolled seizures). However, based upon current evidence, HMG-CoA reductase inhibitor therapy should be continued in the perioperative period unless risk outweighs cardioprotective benefit. Use caution in patients with renal impairment, inadequately treated hypothyroidism, and those taking other drugs associated with myopathy (eg, colchicine); these patients are predisposed to myopathy. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral edema: The most common side effect of amlodipine is peripheral edema (dose dependent); occurs within 2-3 weeks of starting therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use amlodipine with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemorrhagic stroke: Use of atorvastatin in patients with a history of hemorrhagic stroke may increase risk of another hemorrhagic stroke.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment and/or ethanol use: Use atorvastatin with caution in patients who consume large amounts of ethanol or have a history of liver disease; use is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases. Use amlodipine with caution in patients with hepatic impairment; may require lower starting dose; titrate slowly in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use amlodipine with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use atorvastatin with caution in patients taking strong CYP3A4 inhibitors (see Drug Interactions); consider alternative agents that avoid or lessen potential for CYP-mediated. Do not use with cyclosporine, gemfibrozil, tipranavir plus ritonavir, or telaprevir.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use atorvastatin with caution in patients with advanced age, these patients are predisposed to myopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Secondary causes of hyperlipidemia should be ruled out prior to therapy with atorvastatin. Atorvastatin has not been studied when the primary lipid abnormality is chylomicron elevation (Fredrickson types I and V).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Titration: Dosage titration of amlodipine should occur after 7-14 days on a given dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F134146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F134112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: AtorvaSTATin may increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Dose of HMG-CoA reductase inhibitor may need to be reduced (limit simvastatin adult maximum dose to 20 mg/day, limit lovastatin adult maximum dose to 40 mg/day).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of AtorvaSTATin. Management: Limit the atorvastatin maximum adult dose to 40 mg daily in patients receiving boceprevir.  Monitor clinical response to ensure that the lowest necessary atorvastatin dose is used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of AtorvaSTATin. Management: Initiate atorvastatin at the lowest starting dose and titrate up slowly as needed while monitoring closely for evidence of atorvastatin adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Avoid use of statins metabolized by CYP3A4 (eg, simvastatin) and consider avoiding fluvastatin as well in patients receiving high dose cyproterone (300 mg/day). Consider use of pravastatin, rosuvastatin, or pitavastatin if statin therapy is needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: AtorvaSTATin may decrease the serum concentration of Dabigatran Etexilate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Concurrent use of simvastatin with danazol is contraindicated.  Initiate lovastatin at an adult maximum dose of 10 mg/day, and do not exceed 20 mg/day, when danazol is given concomitantly.  Fluvastatin, pravastatin and rosuvastatin may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DAPTOmycin: HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: AtorvaSTATin may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: AtorvaSTATin may increase the serum concentration of Diltiazem. Diltiazem may increase the serum concentration of AtorvaSTATin.  Management: Consider using lower atorvastatin doses when used together with diltiazem.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin, lovastatin and simvastatin. Conversely, levels of fluvastatin may be increased. Management: Dose adjustment of the HMG-CoA reductase inhibitor may be warranted. No interaction is expected with rosuvastatin, pravastatin, or pitavastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use of HMG-CoA reductase inhibitors (statins) with fusidic acid if possible.  If treatment with fusidic acid is necessary, consider temporarily stopping the statin.  With any concurrent use monitor patients closely for statin toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of AtorvaSTATin. Gemfibrozil may increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider avoiding concurrent use of GFJ (especially larger amounts) with lovastatin, simvastatin, or atorvastatin.  Consider using a lower statin dose or a statin that is less likely to interact when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of AmLODIPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of AtorvaSTATin. Management: Limit atorvastatin to a maximum adult dose of 20 mg/day in patients receiving itraconazole.  Assess clinical response to ensure that the lowest necessary dose of atorvastatin is used. Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): AtorvaSTATin may enhance the adverse/toxic effect of Ketoconazole (Systemic). Specifically, there is a theoretical potential for additive effects on reducing endogenous steroid concentrations. Ketoconazole (Systemic) may increase the serum concentration of AtorvaSTATin.  Management: Administer ketoconazole with atorvastatin cautiously, and monitor for toxic effects of atorvastatin (e.g., myalgia, rhabdomyolysis, liver function test abnormalities). Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: HMG-CoA Reductase Inhibitors may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Avoid lovastatin or simvastatin with erythro-, clarithro-, or telithromycin. Limit pitavastatin to a 1 mg/day maximum adult dose with erythromycin.  Atorvastatin dose adjustments may be required. Increase monitoring for toxicity with any such combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: AtorvaSTATin may increase the serum concentration of Midazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: HMG-CoA Reductase Inhibitors may enhance the hepatotoxic effect of Pazopanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in this interaction.  There is a lack of data regarding the risk with other statins, but caution appears warranted with any statins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of AtorvaSTATin. Management: Maximum adult atorvastatin doses: 20 mg/day with darunavir/ritonavir, fosamprenavir, fosamprenavir/ritonavir, saquinavir/ritonavir; 40 mg/day with nelfinavir; lowest necessary dose with lopinavir/ritonavir.  Avoid atorvastatin with tipranavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider using a lower starting dose and lower maintenance/maximum doses of atorvastatin, simvastatin, or lovastatin when used together with quinine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: May decrease the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: AmLODIPine may increase the serum concentration of Simvastatin.  Management: Avoid the concurrent use of amlodipine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day (for adults).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trabectedin: HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: AtorvaSTATin may increase the serum concentration of Verapamil. Verapamil may increase the serum concentration of AtorvaSTATin.  Management: Consider using lower atorvastatin doses when used together with verapamil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of AtorvaSTATin. Management: Monitor for toxic effects of atorvastatin (e.g., myalgia, rhabdomyolysis, liver function test abnormalities) during concomitant treatment, and reduce atorvastatin dose when possible. Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F134131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F134114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F134126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F134140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F134127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F134128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May take with food if desired; may take without regard to time of day. Before initiation of therapy with atorvastatin, patients should be placed on a standard cholesterol-lowering diet for 3-6 months and the diet should be continued during drug therapy. Red yeast rice contains an estimated 2.4 mg lovastatin per 600 mg rice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F134125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Amlodipine-Atorvastatin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-10 mg (30): $151.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-20 mg (30): $206.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-40 mg (30): $206.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-10 mg (90): $453.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-20 mg (90): $620.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-40 mg (90): $620.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-80 mg (30): $206.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-10 mg (90): $453.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-20 mg (90): $620.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-40 mg (90): $620.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-80 mg (30): $206.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Caduet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-10 mg (30): $209.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-20 mg (30): $286.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-40 mg (30): $286.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-10 mg (30): $209.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-20 mg (30): $286.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-40 mg (30): $286.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-80 mg (30): $286.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-10 mg (30): $209.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-20 mg (30): $286.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-40 mg (30): $286.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-80 mg (30): $286.90",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F134116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; baseline CPK (recheck CPK in any patient with symptoms suggestive of myopathy; discontinue therapy if markedly elevated); baseline liver function tests (LFTs) and repeat when clinically indicated thereafter. Patients with elevated transaminase levels should have a second (confirmatory) test and frequent monitoring until values normalize; discontinue if increase in ALT/AST is persistently &gt;3 times ULN (NCEP, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Lipid panel (total cholesterol, HDL, LDL, triglycerides):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      ATP III recommendations (NCEP, 2002):",
"     </i>",
"     Baseline; 6-8 weeks after initiation of drug therapy; if dose increased, then at 6-8 weeks until final dose determined. Once treatment goal achieved, follow-up intervals may be reduced to every 4-6 months. Lipid panel should be assessed at least annually, and preferably at each clinic visit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Manufacturer recommendation:",
"     </i>",
"     Upon initiation or titration, lipid panel should be analyzed within 2-4 weeks.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4301381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Amat (IN);",
"     </li>",
"     <li>",
"      Caduet (AU, BG, CH, CN, CR, CZ, ES, FR, GT, HK, HN, IL, KP, MX, MY, NI, PA, SG, SV, TH, TW, VE);",
"     </li>",
"     <li>",
"      Encavar (PH);",
"     </li>",
"     <li>",
"      Hipertensal Combi (AR);",
"     </li>",
"     <li>",
"      Liparten (PY);",
"     </li>",
"     <li>",
"      Norvastor (PE);",
"     </li>",
"     <li>",
"      Stamcor (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F134107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     Amlodipine: Inhibits calcium ion from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina. Amlodipine directly acts on vascular smooth muscle to produce peripheral arterial vasodilation reducing peripheral vascular resistance and blood pressure.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Atorvastatin: Inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate limiting enzyme in cholesterol synthesis (reduces the production of mevalonic acid from HMG-CoA); this then results in a compensatory increase in the expression of LDL receptors on hepatocyte membranes and a stimulation of LDL catabolism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F134123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, &ldquo;Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(23):2981-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19529/abstract-text/12479763/pubmed\" id=\"12479763\" target=\"_blank\">",
"        12479763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Castro C and Gourley M, \"Diagnosis and Treatment of Inflammatory Myopathy: Issues and Management,\"",
"      <i>",
"       Ther Adv Musculoskelet Dis",
"      </i>",
"      , 2012, 4(2):111-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19529/abstract-text/22870499/pubmed\" id=\"22870499\" target=\"_blank\">",
"        22870499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Denus S and Spinler SA, &ldquo;Early Statin Therapy for Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2002, 36(11):1749-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19529/abstract-text/12398573/pubmed\" id=\"12398573\" target=\"_blank\">",
"        12398573",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(19):2486-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19529/abstract-text/11368702/pubmed\" id=\"11368702\" target=\"_blank\">",
"        11368702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, \"2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-e118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19529/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grundy SM, Cleeman JI, Merz CN, et al, &ldquo;Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2004, 44(3):720-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19529/abstract-text/15358046/pubmed\" id=\"15358046\" target=\"_blank\">",
"        15358046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heeschen C, Hamm CW, Laufs U, et al, &ldquo;Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2002, 105(12):1446-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19529/abstract-text/11914253/pubmed\" id=\"11914253\" target=\"_blank\">",
"        11914253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19529/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LaRosa JC, Grundy SM, Waters DD, et al, &ldquo;Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(14):1425-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19529/abstract-text/15755765/pubmed\" id=\"15755765\" target=\"_blank\">",
"        15755765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LeManach Y, Godet G, Coriat P, et al, &ldquo;The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 104(6):1326-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19529/abstract-text/17513620/pubmed\" id=\"17513620\" target=\"_blank\">",
"        17513620",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals: A Randomised Placebo-Controlled Trial. Heart Protection Study Collaborative Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9326):7-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19529/abstract-text/12114036/pubmed\" id=\"12114036\" target=\"_blank\">",
"        12114036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nissen SE, Tuzcu EM, Libby P, et al, &ldquo;Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure: The CAMELOT Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 292(18):2217-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19529/abstract-text/15536108/pubmed\" id=\"15536108\" target=\"_blank\">",
"        15536108",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al, &ldquo;ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2002, 33(9):2337-41. Available at file://stroke.ahajournals.org/cgi/content/short/33/9/2337",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19529/abstract-text/12215610/pubmed\" id=\"12215610\" target=\"_blank\">",
"        12215610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poldermans D, Bax JJ, Kertai MD, et al, &ldquo;Statins Are Associated With a Reduced Incidence of Perioperative Mortality in Patients Undergoing Major Noncardiac Vascular Surgery,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 107(14):1848-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19529/abstract-text/12695283/pubmed\" id=\"12695283\" target=\"_blank\">",
"        12695283",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ridker PM, Danielson E, Fonseca FAH, et al, &ldquo;Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(21):2195-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19529/abstract-text/18997196/pubmed\" id=\"18997196\" target=\"_blank\">",
"        18997196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sever PS, Dahlof B, Poulter NR, et al, &ldquo;Prevention of Coronary and Stroke Events With Atorvastatin in Hypertensive Patients Who Have Average or Lower-Than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid-Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 361(9364):1149-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/4/19529/abstract-text/12686036/pubmed\" id=\"12686036\" target=\"_blank\">",
"        12686036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8680 Version 50.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-13CD9D8202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_4_19529=[""].join("\n");
var outline_f19_4_19529=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134133\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2935689\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134151\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134134\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134145\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984004\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134135\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134136\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134118\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134106\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134121\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134120\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134149\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134124\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134108\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134146\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134112\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134131\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134114\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134126\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134140\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134127\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134128\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134125\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134116\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4301381\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134107\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134123\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8680\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8680|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/8/22661?source=related_link\">",
"      Amlodipine and atorvastatin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_4_19530="Prophylaxis of invasive fungal infections in adults with hematologic malignancies";
var content_f19_4_19530=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prophylaxis of invasive fungal infections in adults with hematologic malignancies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/4/19530/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/4/19530/contributors\">",
"     John R Wingard, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/4/19530/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/4/19530/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/4/19530/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/4/19530/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/4/19530/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H564717498\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive fungal infections are common in high-risk patients with hematologic malignancies, such as patients with acute leukemia receiving induction chemotherapy, and cause substantial morbidity and mortality. The risk for invasive fungal infections increases with the duration and severity of neutropenia, prolonged antibiotic use, and number of chemotherapy cycles.",
"   </p>",
"   <p>",
"    Interest in antifungal prophylaxis for high-risk patients receiving chemotherapy has been prompted by the rising incidence of life-threatening invasive fungal infections among cancer patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/1\">",
"     1",
"    </a>",
"    ], the difficulty in establishing the diagnosis early in the course of infection, and the recognition that treatment outcomes are poor if initiation of therapy is delayed.",
"   </p>",
"   <p>",
"    The epidemiology and prophylaxis of invasive fungal infections in patients with hematologic malignancies will be discussed here. The epidemiology and prophylaxis of invasive fungal infections in hematopoietic cell transplant recipients are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other important issues related to infections in patients with hematologic malignancies are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link\">",
"       \"Overview of neutropenic fever syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=see_link\">",
"       \"Diagnostic approach to the adult presenting with neutropenic fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"       \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=see_link\">",
"       \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link&amp;anchor=H1169494839#H1169494839\">",
"       \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\", section on 'Initial regimen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link\">",
"       \"Treatment of candidemia and invasive candidiasis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"       \"Treatment and prevention of invasive aspergillosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link\">",
"       \"Mucormycosis (zygomycosis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=see_link\">",
"       \"Treatment and prevention of Fusarium infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564717505\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both yeasts and molds cause serious invasive fungal infections in patients with hematologic malignancies. Prior to the routine use of antifungal prophylaxis, Candida spp accounted for the majority of fungal infections that occurred during neutropenia, followed by Aspergillus spp [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. More recently, Aspergillus has surpassed Candida as a cause of invasive fungal infections in patients with hematologic malignancies, likely due to the use of antifungal prophylaxis targeting Candida spp [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Both pathogens are associated with substantial risk for mortality.",
"   </p>",
"   <p>",
"    In an autopsy study of patients who died after prolonged neutropenic fever between 1966 and 1975, rising rates of fungal infection were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/2\">",
"     2",
"    </a>",
"    ]. Over half of the patients in this early series had Candida infections, which may have been effectively prevented with antifungal prophylaxis. For example, in one trial, fungal infections were documented in only 1 percent of patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    prophylaxis who had persistent fevers despite receiving broad-spectrum antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564717552\">",
"    <span class=\"h2\">",
"     Candida infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida is the most important yeast pathogen, accounting for most invasive yeast infections [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/9\">",
"     9",
"    </a>",
"    ]. The incidence of invasive candidiasis in patients with hematologic malignancies has varied widely in different studies, likely due to differences in the underlying disease (eg, newly diagnosed, in remission, relapsed or refractory to treatment), the duration of neutropenia, and the types of chemotherapy regimens used [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/10\">",
"     10",
"    </a>",
"    ]. Rates of invasive Candida infection in patients with hematologic malignancies not receiving antifungal prophylaxis have ranged from 8 to 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/11-16\">",
"     11-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although Candida is ordinarily a harmless colonizer of mucosal surfaces and skin, breeches in skin or mucosal integrity can lead to invasion of deep tissues and hematogenous dissemination. The portal of entry for this commensal organism is thought to be primarily the gastrointestinal tract in this patient population, with translocation occurring as a result of mucosal injury from cytotoxic chemotherapy. Candidemia is the most frequent clinical manifestation of invasive candidiasis. Candida is also a common fungal cause of central venous catheter-associated infections. Less commonly, Candida causes disseminated candidiasis, including chronic disseminated candidiasis (hepatosplenic candidiasis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=see_link\">",
"     \"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10071?source=see_link\">",
"     \"Hepatosplenic candidiasis (chronic disseminated candidiasis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with acute leukemia are at highest risk for invasive candidiasis during the period of neutropenia that follows induction chemotherapy. Although C. albicans accounts for about half of invasive Candida infections, patients with hematologic malignancies and hematopoietic cell transplant recipients are also at increased risk for infections caused by non-albicans Candida species (eg, C. glabrata, C. tropicalis) compared with other types of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and pathogenesis of candidemia in adults\", section on 'Prevalence of Candida species'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564717559\">",
"    <span class=\"h2\">",
"     Aspergillus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspergillus is the most common mold pathogen in patients with hematologic malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/5\">",
"     5",
"    </a>",
"    ]. In patients with acute myelogenous leukemia (AML), the incidence of invasive aspergillosis has ranged from 2 to 28 percent, with most studies reporting rates between 5 and 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/10\">",
"     10",
"    </a>",
"    ]. In such patients, the risk varies according to the disease status; patients with relapsed or refractory AML receiving salvage chemotherapy are at the greatest risk, whereas newly-diagnosed patients receiving induction chemotherapy are at lower risk. AML patients in remission who are receiving consolidation chemotherapy are at the lowest risk.",
"   </p>",
"   <p>",
"    The usual portal of entry of this airborne organism is inhalation into the sinuses and respiratory tract. The most frequent manifestation of invasive aspergillosis is pneumonia. Pulmonary infiltrates due to Aspergillus typically consist of one or more nodules with or without surrounding ground glass opacities (the halo sign), cavities, air-crescent signs, or focal airspace consolidation. Other manifestations include sinusitis, localized skin ulcers, subcutaneous nodules, cerebral infarction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fulminant disseminated disease.",
"   </p>",
"   <p>",
"    A. fumigatus is the most common Aspergillus species to cause disease, but several other Aspergillus species also cause invasive disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564717578\">",
"    <span class=\"h2\">",
"     Other fungal infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The agents of mucormycosis are the second most common cause of mold infections in patients with hematologic malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], but are infrequent overall at most centers. Mucormycosis can cause life-threatening rhino-orbital, pulmonary, cerebral,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disseminated infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link&amp;anchor=H5#H5\">",
"     \"Mucormycosis (zygomycosis)\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fusarium spp and Scedosporium spp have also been reported in patients with hematologic malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=see_link\">",
"     \"Mycology, pathogenesis, and epidemiology of Fusarium infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41640?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Scedosporium infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although reactivation of endemic fungi (histoplasmosis, blastomycosis, and coccidioidomycosis) is uncommon in patients with hematologic malignancies, these fungi should also be considered in patients with prolonged glucocorticoid use or other immunosuppression who have lived in or traveled to endemic areas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=see_link\">",
"     \"Pathogenesis and clinical features of pulmonary histoplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/79?source=see_link\">",
"     \"Mycology, pathogenesis, and epidemiology of blastomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564717631\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564717639\">",
"    <span class=\"h2\">",
"     Acute leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with hematologic malignancies, the incidence of fungal infection (especially those caused by Candida or Aspergillus spp) rises after patients have experienced more than seven days of persistent fever and neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/21\">",
"     21",
"    </a>",
"    ]. The major risk factor for invasive candidiasis is receiving an intensive induction regimen for acute leukemia that causes severe oral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gastrointestinal mucosal injury. Other contributory risk factors are use of broad-spectrum antibiotics and presence of a central venous catheter.",
"   </p>",
"   <p>",
"    Risk factors for invasive aspergillosis in patients with hematologic malignancies are advanced or refractory acute myelogenous leukemia or high-risk myelodysplastic syndrome, the need to administer multiple chemotherapy regimens to attempt to achieve remission, iron overload from multiple erythrocyte transfusions, chronic neutropenia before initiation of chemotherapy, and prior aspergillosis during previous treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/21-25\">",
"     21-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564717671\">",
"    <span class=\"h2\">",
"     Other patients at risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic cell transplantation (HCT), particularly allogeneic HCT, confers substantial risk for invasive fungal infections. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link&amp;anchor=H20422834#H20422834\">",
"     \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compared with patients with acute leukemia and HCT recipients, the risk for invasive fungal infections is lower in patients with chronic leukemias, lymphoma, and multiple myeloma, but invasive fungal infections do occur in such patients.",
"   </p>",
"   <p>",
"    Therapies that suppress T-cell immunity increase susceptibility to invasive fungal infections, including Candida and Aspergillus infections. Such regimens include intensive glucocorticoid therapy, use of antithymocyte globulin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    , and purine analogs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=see_link&amp;anchor=H22#H22\">",
"     \"Glucocorticoid effects on the immune system\", section on 'Infection risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=see_link\">",
"     \"Overview of infectious complications following purine analog therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2858590\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines have been developed by several organizations for the prevention of invasive fungal infections in patients with malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. The recommendations below are generally in keeping with the 2010 Infectious Diseases Society of America (IDSA) guidelines for the use of antimicrobial agents in neutropenic patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/26\">",
"     26",
"    </a>",
"    ]. These and other IDSA guidelines can be accessed through the",
"    <a class=\"external\" href=\"file://www.idsociety.org/IDSA_Practice_Guidelines/\">",
"     IDSA&rsquo;s web site",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Practices for antifungal prophylaxis vary widely. Some cancer centers have developed their own protocols for antifungal prophylaxis, which depend at least in part upon local rates of resistance, as well as the overall risk of invasive fungal infections based upon which chemotherapeutic regimens are used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69318194\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564717685\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary prophylaxis involves the administration of an antimicrobial agent to prevent infection in patients at increased risk who have not previously had the type of infection being targeted. The benefits of primary antifungal prophylaxis have been observed in multiple studies. Much of the emphasis historically has been on the prevention of Candida infections. However, studies of Aspergillus prevention have intensified in recent years.",
"   </p>",
"   <p>",
"    A 2007 meta-analysis that included 64 randomized trials compared systemic antifungal prophylaxis (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ) with a control arm (placebo, no intervention, or a non-systemic antifungal agent such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    ) in cancer patients receiving myelosuppressive chemotherapy (predominantly for acute leukemia) or undergoing hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/31\">",
"     31",
"    </a>",
"    ]. In patients with acute leukemia, antifungal prophylaxis was associated with significant reductions in fungal-related mortality (relative risk [RR] 0.66, 95% CI 0.44-1.00) and documented invasive fungal infections (RR 0.69, 95% CI 0.53-0.90). However, antifungal prophylaxis was associated with only a non-significant trend towards a reduction in all-cause mortality (RR 0.88, 95% CI 0.74-1.06).",
"   </p>",
"   <p>",
"    A 2012 meta-analysis that included 20 randomized trials compared mold-active prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    prophylaxis in patients with hematologic malignancy receiving chemotherapy (6 trials) or HCT recipients (14 trials) with the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mold-active prophylaxis reduced the number of proven or probable invasive fungal infections compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      prophylaxis (RR 0.71, 95% CI 0.52-0.98).",
"     </li>",
"     <li>",
"      Mold-active prophylaxis reduced the risk of invasive aspergillosis compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      prophylaxis (RR 0.53, 95% CI 0.37-0.75).",
"     </li>",
"     <li>",
"      Mold-active prophylaxis reduced the risk of invasive fungal infection-related mortality compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      prophylaxis (RR 0.67, 95% CI 0.47-0.96).",
"     </li>",
"     <li>",
"      There was no difference in overall mortality between patients who received mold-active prophylaxis and those who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      prophylaxis.",
"     </li>",
"     <li>",
"      Mold-active prophylaxis was associated with an increased risk of adverse events leading to antifungal discontinuation (RR 1.95, 95% CI 1.24-3.07).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564717692\">",
"    <span class=\"h3\">",
"     Candida infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 2007 meta-analysis described above, antifungal prophylaxis resulted in a significant reduction in invasive Candida infections in patients with acute leukemia and HCT recipients (RR 0.31, 95% CI 0.23-0.41) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/31\">",
"     31",
"    </a>",
"    ]. In a subgroup analysis of patients with acute leukemia, the reduction in invasive Candida infections remained statistically significant.",
"    <br/>",
"   </p>",
"   <p>",
"    Meta-analyses and randomized trials have determined that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is efficacious in preventing Candida infections in high-risk patients; the incidence at which this can be appreciated is at or above 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/11,31,33,34\">",
"     11,31,33,34",
"    </a>",
"    ]. Infection rates at or above this threshold are seen primarily in patients undergoing intensive induction chemotherapy for acute myelogenous leukemia with severe oral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gastrointestinal mucositis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69316976\">",
"    <span class=\"h4\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    has been studied most rigorously for Candida prophylaxis, other agents have also been evaluated and are considered acceptable alternatives, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/26\">",
"     26",
"    </a>",
"    ]. We also believe that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    is a reasonable option, since it has the same spectrum of activity as micafungin and caspofungin.",
"   </p>",
"   <p>",
"    When Candida prophylaxis is indicated, we favor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    . Fluconazole has the advantage of being available as both oral and intravenous formulations, excellent tolerability, inexpensive generic formulations, and less severe interactions with concomitant medications compared to the extended-spectrum azoles.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    has several important drawbacks, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Its spectrum of activity against Candida spp is narrower than the echinocandins.",
"     </li>",
"     <li>",
"      Breakthrough infections with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      -resistant Candida species, especially C. krusei and C. glabrata, have been reported.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"      has no activity against Aspergillus or other molds, in comparison to the other acceptable agents, which have at least some activity against Aspergillus spp.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternative agents have the following benefits and drawbacks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Echinocandins",
"      </strong>",
"      &ndash; The echinocandins (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       micafungin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       anidulafungin",
"      </a>",
"      ) have a broader spectrum of activity than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      , with most common Candida species being susceptible, and an excellent safety record. The drawbacks of this antifungal class are its availability only as an intravenous formulation and its high cost. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9338?source=see_link\">",
"       \"Pharmacology of echinocandins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Itraconazole is available widely as an oral formulation; the intravenous formulation has been withdrawn in the United States, but remains available in some countries. The oral formulation is poorly tolerated and has variable bioavailability. Another major drawback is its potential interactions with certain chemotherapy agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H7#H7\">",
"       \"Pharmacology of azoles\", section on 'Itraconazole'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H22#H22\">",
"       \"Pharmacology of azoles\", section on 'Itraconazole'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H564717713\">",
"       'Drug interactions'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      &ndash; Voriconazole has both oral and IV formulations but has been noted to cause transient visual disturbances (that are not permanent or serious) and may cause more hepatotoxicity than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      . A major drawback is its potential interactions with certain chemotherapy agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H16#H16\">",
"       \"Pharmacology of azoles\", section on 'Voriconazole'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H28#H28\">",
"       \"Pharmacology of azoles\", section on 'Voriconazole'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H564717713\">",
"       'Drug interactions'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       Posaconazole",
"      </a>",
"      &ndash; Posaconazole is available only as an oral formulation. It has been evaluated primarily for its anti-mold activity, but in trials, low rates of Candida infections were noted, and posaconazole is therefore an option for anti-yeast prevention [",
"      <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/22\">",
"       22",
"      </a>",
"      ]. Its major drawbacks include lack of an IV formulation and variability of blood levels after oral administration, as well as its potential interactions with certain chemotherapy agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"       \"Pharmacology of azoles\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564717699\">",
"    <span class=\"h3\">",
"     Aspergillus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for Aspergillus prophylaxis for high-risk neutropenic patients varies according to the underlying disease and its therapy. Several trials suggest that the risk-benefit ratio favors prophylaxis when the rate of invasive aspergillosis is at least 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/22,35\">",
"     22,35",
"    </a>",
"    ]. Aspergillus prophylaxis has been demonstrated to be beneficial in patients with acute myelogenous leukemia (AML) or advanced myelodysplastic syndrome (MDS) receiving induction chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of antifungal agents with activity against Aspergillus spp and other molds (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    formulations) has been evaluated in various studies. A meta-analysis that compared mold-active prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    prophylaxis is discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H564717685\">",
"     'Primary prophylaxis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    All of the agents with activity against molds also have activity against Candida spp. We prefer either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    for anti-mold prophylaxis in this patient population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18984029\">",
"    <span class=\"h4\">",
"     Posaconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    is an extended-spectrum triazole with activity against Aspergillus spp and the agents of mucormycosis. Posaconazole was compared with the standard azole used at participating centers (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ) in a multicenter randomized open-label trial of 602 patients 13 years of age or older with prolonged neutropenia due to chemotherapy for AML or advanced MDS [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/22\">",
"     22",
"    </a>",
"    ]. Prophylaxis was given with each cycle of chemotherapy until recovery from neutropenia and complete remission, occurrence of an invasive fungal infection, or for up to 12 weeks, whichever came first.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    prophylaxis was associated with a significant reduction in proven or probable invasive fungal infections (2 versus 8 percent) that was due entirely to a reduction in invasive aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/22\">",
"     22",
"    </a>",
"    ]. Posaconazole was also associated with a significant reduction in all-cause mortality (16 versus 22 percent).",
"   </p>",
"   <p>",
"    However, severe serious adverse events attributable to the drug were significantly more common with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    (6 versus 2 percent), although the rate of toxicity of all causes was similar between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/22\">",
"     22",
"    </a>",
"    ]. It is not known whether the adverse events that were attributable to the study drug were more common in patients who received chemotherapy concomitantly with posaconazole. Given the potential for serious drug interactions, concomitant administration of posaconazole and the other extended-spectrum triazoles (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ) should be avoided in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    or high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . Caution is also advised for concomitant use of the extended-spectrum triazoles with chemotherapy drugs metabolized by the liver, especially those metabolized by cytochrome P450 isoenzymes (see",
"    <a class=\"local\" href=\"#H564717713\">",
"     'Drug interactions'",
"    </a>",
"    below). Clinicians should also consider an interval of several days of azole drug washout when considering initiation of chemotherapy regimens that may interact.",
"   </p>",
"   <p>",
"    It is important to note that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    &rsquo;s absorption is greatly improved by concomitant food (especially high-fat food); if the patient is not eating, absorption is greatly impeded and it is unlikely that blood posaconazole levels will be adequate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H30#H30\">",
"     \"Pharmacology of azoles\", section on 'Posaconazole'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148200\">",
"    <span class=\"h4\">",
"     Voriconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    has activity against Aspergillus spp, but not against the agents of mucormycosis. Although voriconazole is used in some centers, there are no large randomized trials evaluating the possible benefit of this agent for prophylaxis in patients with AML or MDS receiving induction chemotherapy. However, a large randomized trial was performed during the preengraftment period in hematopoietic cell transplant (HCT) recipients, many of whom had AML [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/36\">",
"     36",
"    </a>",
"    ]. Among patients who received voriconazole compared with those who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , fungal-free survival (the primary endpoint, defined as freedom from an invasive fungal infection or death at 180 days) was similar (78 versus 75 percent). There were trends toward fewer invasive fungal infections (7 versus 11 percent), Aspergillus infections (9 versus 17), and less frequent use of empiric antifungal therapy (24 versus 30 percent) in patients who received voriconazole compared with those who received fluconazole. In a post-hoc analysis of HCT recipients with AML, those who received voriconazole had significantly improved fungal-free survival (78 versus 61 percent) and significantly fewer invasive fungal infections (9 versus 21 percent), but no difference in overall survival (81 versus 72 percent) compared with those who received fluconazole. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link&amp;anchor=H232631507#H232631507\">",
"     \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\", section on 'Prophylaxis during the preengraftment period'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    has been best evaluated for the treatment of invasive aspergillosis; it is the preferred agent for treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18984037\">",
"    <span class=\"h4\">",
"     Itraconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    has activity against Aspergillus spp. Two meta-analyses concluded that itraconazole was effective for preventing invasive fungal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], but one found that the protective effect from prophylaxis was limited to trials using itraconazole oral solution (at a dose of 200 mg twice daily), a preparation that is poorly tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/38\">",
"     38",
"    </a>",
"    ]. Itraconazole&rsquo;s absorption is greatly affected by the formulation (oral solution greater than oral capsule), gastric acidity, and concomitant food intake.",
"   </p>",
"   <p>",
"    There are deleterious interactions with certain chemotherapy agents (best documented with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and vinca alkaloids) that can be serious, and concomitant use should be avoided. All of the extended-spectrum azoles (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ) have the potential for deleterious interactions with certain chemotherapy agents. (See",
"    <a class=\"local\" href=\"#H564717713\">",
"     'Drug interactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18984053\">",
"    <span class=\"h4\">",
"     Amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    formulations have activity against Aspergillus spp and the agents of mucormycosis as well as Candida spp, but they are generally not used for antifungal prophylaxis due to their adverse effects and insufficient evidence regarding their efficacy. Amphotericin B deoxycholate given parenterally has been plagued by infusional toxicities and nephrotoxicity, and its efficacy as prophylaxis is not well established. Some studies in patients with hematologic malignancies have suggested a benefit of the prophylactic use of lipid formulations of amphotericin B given parenterally [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/12\">",
"     12",
"    </a>",
"    ], whereas others have not [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Unfortunately, several of these trials were underpowered to provide definitive answers. The possible efficacy of lipid formulations of amphotericin B for antifungal prophylaxis has been insufficiently studied to date. Although the lipid formulations of amphotericin B are less toxic than amphotericin B deoxycholate, adverse effects are still substantial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link&amp;anchor=H17#H17\">",
"     \"Pharmacology of amphotericin B\", section on 'Safety and efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    in preventing invasive pulmonary aspergillosis was evaluated in a randomized, placebo-controlled trial of 271 patients with hematologic malignancies (during 407 neutropenic episodes) who were expected to be neutropenic for at least 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/42\">",
"     42",
"    </a>",
"    ]. All patients received anti-yeast prophylaxis to prevent Candida infection. In the intent-to-treat analysis, aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    was associated with a significant reduction in the rate of invasive aspergillosis compared with placebo (4.3 versus 13.6 percent, odds ratio 0.26, 95% CI 0.09-0.72). No survival benefit was observed, but this study was probably underpowered to detect such an effect. There was a significantly greater incidence of adverse events, primarily cough, preventing adherence to the drug administration in a sizable proportion of patients.",
"   </p>",
"   <p>",
"    Aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    has not been directly compared to systemic antifungal prophylaxis. Thus, additional studies are needed before this therapy can be recommended for patients who require antifungal prophylaxis. It is also important to note that droplet size is crucial to ensure delivery of the drug to the lower respiratory tract and may vary from one delivery device to another.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    given as an oral suspension or lozenge has had some benefit in reducing superficial infections (mostly Candida), but has not had a consistent benefit in reducing systemic or invasive infections [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/29\">",
"     29",
"    </a>",
"    ]. This is not surprising since the usual portals of entry for Aspergillus spp and other molds are the sinuses and respiratory tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69317229\">",
"    <span class=\"h3\">",
"     Risk-benefit assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although antifungal prophylaxis has been proven to be efficacious in selected high-risk patients with hematologic malignancies, issues surrounding overuse of antifungal agents (eg, resistance, toxicity, and cost) and the relatively low incidence of invasive fungal infections in these patients have tempered enthusiasm for universal prophylaxis. The risk-benefit analysis must include an assessment of the relative level of immunosuppression and comorbidities to identify those individuals at increased risk for invasive fungal infections. The level of immunosuppression is higher after induction chemotherapy for acute leukemia compared to other settings, such as following consolidation chemotherapy. Important comorbidities include older age, the presence or absence of mucositis, poorly controlled diabetes, smoking history, iron overload from transfusions, and recurrent use of antibacterial agents.",
"   </p>",
"   <p>",
"    Factors that support the use of antifungal prophylaxis in high-risk patients include the substantial morbidity and mortality of invasive fungal infections and the difficulty in obtaining a timely diagnosis due to the limitations of available diagnostic tests [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564717727\">",
"    <span class=\"h3\">",
"     Approach to primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations represent our approach to antifungal prophylaxis in patients with hematologic malignancies. These recommendations are generally in keeping with the Infectious Diseases Society of America guidelines for the use of antimicrobial agents in neutropenic patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/26\">",
"     26",
"    </a>",
"    ]. It should be noted that there is ongoing controversy about the use of antifungal prophylaxis (see",
"    <a class=\"local\" href=\"#H69317229\">",
"     'Risk-benefit assessment'",
"    </a>",
"    above). As a result, practices regarding antifungal prophylaxis differ widely at various cancer centers, and our approach may be different from the approach recommended at a specific institution.",
"   </p>",
"   <p>",
"    We favor the following approach to primary antifungal prophylaxis in patients with acute leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with acute leukemia undergoing remission-induction or salvage-induction chemotherapy who are expected to develop severe oral",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gastrointestinal mucositis, we recommend prophylaxis against Candida infections. We prefer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (200 or 400 mg orally once daily), but alternative agents may be given. Alternative agents include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       micafungin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       anidulafungin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H564717692\">",
"       'Candida infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For selected patients who are undergoing intensive chemotherapy for acute myelogenous leukemia or advanced myelodysplastic syndrome, we suggest prophylaxis against invasive mold infections and Candida spp with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      (200 mg orally three times daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (200 mg orally twice daily) rather than targeted anti-Candida prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H564717699\">",
"       'Aspergillus infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antifungal prophylaxis is",
"      <strong>",
"       not",
"      </strong>",
"      recommended for patients in whom the anticipated duration of neutropenia is &lt;7 days.",
"     </li>",
"     <li>",
"      Given the potential for serious drug interactions, concomitant administration of extended-spectrum triazole-based (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      ) prophylaxis should be avoided in patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      or high doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      . Caution is advised for concomitant use of the extended-spectrum triazoles with chemotherapy drugs metabolized by the liver, especially those metabolized by cytochrome P450 isoenzymes. Recommendations about the timing of triazole administration in such patients are discussed below. (See",
"      <a class=\"local\" href=\"#H564717713\">",
"       'Drug interactions'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564717720\">",
"    <span class=\"h2\">",
"     Secondary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have a history of a prior invasive fungal infection, especially Aspergillus infections, are at high risk for recurrence of infection with further antileukemic therapy. This has been best studied in patients with prior Aspergillus infection. Continued treatment after initial control (so-called secondary prophylaxis) can prevent reactivation of infection in most patients and permit further antileukemic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with a history of prior invasive aspergillosis receiving myelosuppressive chemotherapy with an anticipated prolonged neutropenic period of at least two weeks, we recommend antifungal prophylaxis with a mold-active agent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/26\">",
"     26",
"    </a>",
"    ]. The choice of agent depends in part upon the need to avoid drug interactions while chemotherapy is being given.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is the first-line agent for Aspergillus spp and has been best studied as secondary prophylaxis, but mold-active azoles are usually not given concomitantly with certain chemotherapy regimens with hepatically metabolized drugs. Of note, this is not a concern for agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    . This is discussed in greater detail below. (See",
"    <a class=\"local\" href=\"#H564717713\">",
"     'Drug interactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients with prior Candida infections, secondary prophylaxis should be selected based on the Candida species and on which agent was successful in achieving earlier control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69317003\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of antifungal prophylaxis should be individualized based on the patient&rsquo;s clinical status and history of prior fungal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with acute leukemia, primary prophylaxis against Candida spp is typically continued until myeloid reconstitution has occurred.",
"     </li>",
"     <li>",
"      In patients who have a history of a prior invasive fungal infection who are receiving secondary prophylaxis during a period of myelosuppression (eg, during induction chemotherapy in AML patients), prophylaxis is usually continued at least until myeloid reconstitution has occurred. In such patients, follow-up imaging (computed tomography scan of the organ involved in prior infection) and fungal markers (eg, Aspergillus galactomannan antigen, beta-D-glucan) are often obtained two to four weeks after antifungal prophylaxis has been discontinued to ensure that reactivation has not occurred.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69318399\">",
"    <span class=\"h1\">",
"     PREEMPTIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to antifungal prophylaxis involves preemptive therapy. This approach involves targeted screening of high-risk patients for markers of colonization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infection in an attempt to prevent invasive infection. Screening involves checking fungal markers, such as the Aspergillus galactomannan antigen and beta-D-glucan, and chest computed tomography scanning. This approach is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link&amp;anchor=H833586#H833586\">",
"     \"Treatment and prevention of invasive aspergillosis\", section on 'Preemptive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564717706\">",
"    <span class=\"h1\">",
"     BREAKTHROUGH INFECTIONS AND RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Broad use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    prophylaxis has led to increases in Candida species with reduced susceptibility or resistance to fluconazole (eg, C. glabrata, C. krusei) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Cross-resistance to any azole may occur in Candida species, especially C. glabrata [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Thus, prophylaxis should be limited to those patients who are at substantial risk for invasive infection, and one should be mindful of the potential for breakthrough Candida infections, especially with C. krusei or C. glabrata. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=see_link\">",
"     \"Epidemiology and pathogenesis of candidemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An increase in mucormycosis has been reported in several retrospective studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    prophylaxis in several centers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/49-51\">",
"     49-51",
"    </a>",
"    ], but in prospective epidemiologic studies and in controlled prophylaxis trials, mucormycosis remains infrequent and no clear-cut association has been established between voriconazole prophylaxis and the development of mucormycosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link\">",
"     \"Mucormycosis (zygomycosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to note that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    and other echinocandins are not active against Cryptococcus neoformans, Trichosporon, Fusarium, or filamentous molds other than Aspergillus. In addition, some yeasts can demonstrate relative resistance to these drugs (C. parapsilosis, C. rugosa, C. guilliermondii, and non-Candida yeasts). Failure of caspofungin to prevent aspergillosis has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/52\">",
"     52",
"    </a>",
"    ]. Moreover, the clinical efficacy of the echinocandins for endemic fungi (Histoplasma capsulatum, Blastomyces dermatitidis, Coccidioides spp) has not been demonstrated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15210?source=see_link\">",
"     \"Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9321?source=see_link\">",
"     \"Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29912?source=see_link\">",
"     \"Treatment of blastomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26807?source=see_link\">",
"     \"Manifestations and treatment of extrapulmonary coccidioidomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564717713\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many potential drug interactions between antifungal agents and drugs that may be used concomitantly [",
"    <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/53\">",
"     53",
"    </a>",
"    ]. Specific drug interactions unique to patients with hematologic malignancies are mentioned here.",
"   </p>",
"   <p>",
"    The triazoles are metabolized by the cytochrome P450 isoenzymes, and there are multiple potential drug interactions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      has been associated with a harmful interaction with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , resulting in renal and hepatic toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      have been associated with severe neurotoxicity with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      has a potential negative inotropic effect and should be avoided in patients with prior congestive heart failure and drugs that could be cardiotoxic (eg, anthracyclines or high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In a trial of patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      was associated with greater attributable drug toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?19/4/19530/abstract/22\">",
"       22",
"      </a>",
"      ]. However, it is not known whether the adverse events were more common in patients who received chemotherapy concomitantly with posaconazole.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the potential for serious drug interactions, concomitant administration of extended-spectrum triazole-based (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ) prophylaxis should be avoided in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    or high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . Caution is advised for the concomitant use of the extended-spectrum triazoles with chemotherapy drugs metabolized by the liver, especially those metabolized by cytochrome P450 isoenzymes. Of note, this is not a concern for agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    One tactic advised by some experts is to avoid administration of the extended-spectrum triazoles (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ) approximately one week before (to allow clearance) and during chemotherapy and then resume it after chemotherapy to avoid potential drug interactions; if interruption of antifungal drugs will pose a hazard to the patient, another class of antifungal agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    or an echinocandin) can be given during the chemotherapy. Further study of the drug interactions between the extended-spectrum triazoles and chemotherapy drugs is necessary.",
"   </p>",
"   <p>",
"    Some examples of important drug interactions between azoles and other drugs are provided in the Tables (",
"    <a class=\"graphic graphic_table graphicRef66477 \" href=\"UTD.htm?8/51/9021\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55886 \" href=\"UTD.htm?3/6/3181\">",
"     table 2",
"    </a>",
"    ). Drug interactions involving azoles are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H31#H31\">",
"     \"Pharmacology of azoles\", section on 'Drug interactions'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     \"Fluconazole: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     \"Voriconazole: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     \"Itraconazole: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     \"Posaconazole: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, specific interactions of azole agents with other medications may be determined using the drug interaction tool (Lexi-Interact Online). This tool can be accessed from the UpToDate online search page or through the individual drug information topics, section on Drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564717764\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk for invasive fungal infections increases with the duration and severity of neutropenia, prolonged antibiotic use, and number of chemotherapy cycles. (See",
"      <a class=\"local\" href=\"#H564717498\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Candida is by far the most common fungal pathogen in patients with acute leukemia not receiving antifungal prophylaxis. Invasive candidiasis occurs most often as a result of translocation of colonizing Candida spp across the oral",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gastrointestinal mucosa in the setting of mucositis from cytotoxic chemotherapy. Candidemia is the most frequent clinical manifestation of invasive candidiasis. Patients with acute leukemia are at highest risk for invasive candidiasis during induction chemotherapy. (See",
"      <a class=\"local\" href=\"#H564717552\">",
"       'Candida infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aspergillus is the most common mold pathogen in patients with acute leukemia. Its most common manifestation is pneumonia; less common manifestations include sinusitis and disseminated infection. (See",
"      <a class=\"local\" href=\"#H564717559\">",
"       'Aspergillus infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following recommendations represent our approach to antifungal prophylaxis in patients with hematologic malignancies. It should be noted that there is ongoing controversy about the use of antifungal prophylaxis. As a result, practices regarding antifungal prophylaxis differ widely at various cancer centers, and our approach may be different from the approach recommended at a specific institution. (See",
"      <a class=\"local\" href=\"#H564717727\">",
"       'Approach to primary prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H69317229\">",
"       'Risk-benefit assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although antifungal prophylaxis has been proven to be efficacious in selected high-risk patients with hematologic malignancies, issues surrounding overuse of antifungal agents (eg, resistance, toxicity, and cost) and the relatively low incidence of invasive fungal infections in these patients have tempered enthusiasm for universal prophylaxis. The risk-benefit analysis must include an assessment of the relative level of immunosuppression and comorbidities to identify those individuals at increased risk for invasive fungal infections. (See",
"      <a class=\"local\" href=\"#H69317229\">",
"       'Risk-benefit assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with acute leukemia undergoing remission-induction or salvage-induction chemotherapy who are expected to develop severe oral",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gastrointestinal mucositis, we recommend prophylaxis against Candida infections (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We prefer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (200 or 400 mg orally once daily), but alternative agents may be given. Alternative agents include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       micafungin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       anidulafungin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H564717727\">",
"       'Approach to primary prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For selected patients who are undergoing intensive chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome, we suggest prophylaxis against both invasive mold infections and Candida spp rather than targeted anti-Candida prophylaxis; in such patients, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      (200 mg orally three times daily) (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (200 mg orally twice daily) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H564717727\">",
"       'Approach to primary prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a history of prior invasive aspergillosis receiving myelosuppressive chemotherapy with an anticipated prolonged neutropenic period of at least two weeks, we recommend secondary antifungal prophylaxis with a mold-active agent (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H564717720\">",
"       'Secondary prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the potential for serious drug interactions, concomitant administration of extended-spectrum triazole-based (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      ) prophylaxis should be avoided in patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      or high doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      . Caution is advised for concomitant use of the extended-spectrum azoles with chemotherapy drugs metabolized by the liver, especially those metabolized by cytochrome P450 isoenzymes. (See",
"      <a class=\"local\" href=\"#H564717713\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564717512\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Richard A Larson, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/1\">",
"      Pfaffenbach B, Donhuijsen K, Pahnke J, et al. [Systemic fungal infections in hematologic neoplasms. An autopsy study of 1,053 patients]. Med Klin (Munich) 1994; 89:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/2\">",
"      Cho SY, Choi HY. Opportunistic fungal infection among cancer patients. A ten-year autopsy study. Am J Clin Pathol 1979; 72:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/3\">",
"      Bodey GP. Fungal infections complicating acute leukemia. J Chronic Dis 1966; 19:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/4\">",
"      Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/5\">",
"      Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/6\">",
"      Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/7\">",
"      Donhuijsen K, Petersen P, Schmid WK. Trend reversal in the frequency of mycoses in hematological neoplasias: autopsy results from 1976 to 2005. Dtsch Arztebl Int 2008; 105:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/8\">",
"      Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/9\">",
"      Hachem R, Hanna H, Kontoyiannis D, et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008; 112:2493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/10\">",
"      Wirk B, Wingard JR. Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients. Mycopathologia 2009; 168:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/11\">",
"      Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/12\">",
"      Penack O, Schwartz S, Martus P, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006; 17:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/13\">",
"      Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 1999; 28:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/14\">",
"      Nucci M, Biasoli I, Akiti T, et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 2000; 30:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/15\">",
"      Wingard JR, Vaughan WP, Braine HG, et al. Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole. Am J Med 1987; 83:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/16\">",
"      Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/17\">",
"      Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/18\">",
"      Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/19\">",
"      Wingard JR. Zygomycosis: epidemiology and treatment options. Proceedings of Johns Hopkins Advanced Studies in Medicine 2006; 6:S526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/20\">",
"      Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 2003; 16:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/21\">",
"      Wingard JR, Leather HL. Empiric antifungal therapy for the neutropenic patient. Oncology (Williston Park) 2001; 15:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/22\">",
"      Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/23\">",
"      Lortholary O, Gangneux JP, Sitbon K, et al. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007). Clin Microbiol Infect 2011; 17:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/24\">",
"      Pagano L, Akova M, Dimopoulos G, et al. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother 2011; 66 Suppl 1:i5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/25\">",
"      Kontoyiannis DP, Chamilos G, Lewis RE, et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 2007; 110:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/26\">",
"      Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 1.2012. file://www.nccn.org (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/28\">",
"      Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update. Bone Marrow Transplant 2011; 46:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/29\">",
"      Cornely OA, B&ouml;hme A, Buchheidt D, et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2009; 94:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/30\">",
"      Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/31\">",
"      Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007; 25:5471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/32\">",
"      Ethier MC, Science M, Beyene J, et al. Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials. Br J Cancer 2012; 106:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/33\">",
"      Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000; 89:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/34\">",
"      Bow EJ, Laverdi&egrave;re M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002; 94:3230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/35\">",
"      Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/36\">",
"      Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116:5111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/37\">",
"      Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 2005; 131:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/38\">",
"      Glasmacher A, Prentice A, Gorschl&uuml;ter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21:4615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/39\">",
"      Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/40\">",
"      Cordonnier C, Mohty M, Faucher C, et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. Int J Antimicrob Agents 2008; 31:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/41\">",
"      Timmers GJ, Zweegman S, Simoons-Smit AM, et al. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplant 2000; 25:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/42\">",
"      Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/43\">",
"      Karp JE, Burch PA, Merz WG. An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis. Am J Med 1988; 85:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/44\">",
"      Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/45\">",
"      Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/46\">",
"      Wingard JR, Merz WG, Rinaldi MG, et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/47\">",
"      Pfaller MA, Messer SA, Boyken L, et al. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004; 42:3142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/48\">",
"      Tsai HF, Bard M, Izumikawa K, et al. Candida glabrata erg1 mutant with increased sensitivity to azoles and to low oxygen tension. Antimicrob Agents Chemother 2004; 48:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/49\">",
"      Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/50\">",
"      Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/51\">",
"      Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/52\">",
"      Madureira A, Bergeron A, Lacroix C, et al. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents 2007; 30:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/53\">",
"      Gubbins PO, Heldenbrand S. Clinically relevant drug interactions of current antifungal agents. Mycoses 2010; 53:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/54\">",
"      Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/4/19530/abstract/55\">",
"      Pana ZD, Roilides E. Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: old problem - new dilemma. Pediatr Blood Cancer 2011; 57:30.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16141 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-E64CDCC3B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_4_19530=[""].join("\n");
var outline_f19_4_19530=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H564717764\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H564717498\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H564717505\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H564717552\">",
"      Candida infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H564717559\">",
"      Aspergillus infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H564717578\">",
"      Other fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H564717631\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H564717639\">",
"      Acute leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H564717671\">",
"      Other patients at risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2858590\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69318194\">",
"      PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H564717685\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H564717692\">",
"      - Candida infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H69316976\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H564717699\">",
"      - Aspergillus infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18984029\">",
"      Posaconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H148200\">",
"      Voriconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18984037\">",
"      Itraconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18984053\">",
"      Amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H69317229\">",
"      - Risk-benefit assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H564717727\">",
"      - Approach to primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H564717720\">",
"      Secondary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69317003\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69318399\">",
"      PREEMPTIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H564717706\">",
"      BREAKTHROUGH INFECTIONS AND RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H564717713\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H564717764\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H564717512\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/16141\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16141|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/51/9021\" title=\"table 1\">",
"      Significant interactions involving triazoles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/6/3181\" title=\"table 2\">",
"      Major interactions involving triazoles",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=related_link\">",
"      Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9321?source=related_link\">",
"      Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=related_link\">",
"      Diagnostic approach to the adult presenting with neutropenic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41640?source=related_link\">",
"      Epidemiology and clinical manifestations of Scedosporium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=related_link\">",
"      Epidemiology and pathogenesis of candidemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=related_link\">",
"      Fluconazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=related_link\">",
"      Glucocorticoid effects on the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10071?source=related_link\">",
"      Hepatosplenic candidiasis (chronic disseminated candidiasis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=related_link\">",
"      Itraconazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26807?source=related_link\">",
"      Manifestations and treatment of extrapulmonary coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/79?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of blastomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=related_link\">",
"      Overview of infectious complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=related_link\">",
"      Pathogenesis and clinical features of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9338?source=related_link\">",
"      Pharmacology of echinocandins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=related_link\">",
"      Posaconazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=related_link\">",
"      Primary coccidioidal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=related_link\">",
"      Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=related_link\">",
"      Treatment and prevention of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=related_link\">",
"      Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29912?source=related_link\">",
"      Treatment of blastomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15210?source=related_link\">",
"      Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=related_link\">",
"      Voriconazole: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_4_19531="Causes of congenital goiter";
var content_f19_4_19531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F71540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F71540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of congenital goiter",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inborn errors of thyroid hormone production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dyshormonogenesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Transplacental passage of maternal antibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TSH-receptor blocking antibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TSH-receptor stimulating antibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Maternal ingestion of antithyroid drugs and other goitrogens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propylthiouracil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methimazole or carbamazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iodine and iodine-containing drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Activating mutations of the TSH receptor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital nonimmune hyperthyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Activating mutations of the G protein alpha subunit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        McCune-Albright syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Thyroid hemiagenesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Thyroid tumors",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_4_19531=[""].join("\n");
var outline_f19_4_19531=null;
var title_f19_4_19532="Clues for chronic meningitis";
var content_f19_4_19532=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinically useful or important clues to the cause of chronic meningitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clue",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positive tuberculin skin test",
"       </td>",
"       <td>",
"        Tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Residence or travel to the Southwestern United States, Southern California or Mexico",
"       </td>",
"       <td>",
"        Coccidioidomycosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothalamic, optic or pituitary lesions on cranial imaging",
"       </td>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uveitis/iritis",
"       </td>",
"       <td>",
"        Sarcoidosis, Behcet's disease, Vogt-Koyanagi-Harada syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiculopathy and/or cranial nerve palsies",
"       </td>",
"       <td>",
"        Lyme disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prior residence in Mexico, Central or South America, India, Sub-Saharan Africa or the Caribbean",
"       </td>",
"       <td>",
"        Cysticercosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exposure to unpasturized milk or contact with cows, goats, swine or sheep (including butchering or working in a packing house)",
"       </td>",
"       <td>",
"        Brucellosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral 7th nerve paralysis",
"       </td>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes insipidus",
"       </td>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poliosis (whitening of the eyebrows and eyelashes and vitiligo)",
"       </td>",
"       <td>",
"        Vogt-Koyanagi-Harada syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent genital or oral ulcerations",
"       </td>",
"       <td>",
"        Behcet's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A preexisting immunosuppressive condition or therapy",
"       </td>",
"       <td>",
"        Cryptococcosis, tuberculosis, toxoplasmosis, endemic mycoses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Predominately neutrophilic cerebrospinal fluid (CSF) pleocytosis",
"       </td>",
"       <td>",
"        Nocardiosis, actinomycosis, aspergillosis, systemic lupus erythematosus, chemical or drug-induced meningitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eosinophilic CSF pleocytosis",
"       </td>",
"       <td>",
"        Coccidioidomycosis, lymphoma, Angiostrongylus, cysticercosis, schistosomiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypogammaglobulinemia",
"       </td>",
"       <td>",
"        Echovirus",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_4_19532=[""].join("\n");
var outline_f19_4_19532=null;
var title_f19_4_19533="Yield of repeat screening";
var content_f19_4_19533=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The decreasing yield of a screening test after the first round of screening",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 270px; height: 345px; background-image: url(data:image/gif;base64,R0lGODlhDgFZAcQAAP///4CAgAAAAEBAQMDAwFBQUBAQEODg4NDQ0KCgoCAgIC8vL/Dw8K+vr3BwcLCwsDAwMGBgYJCQkO/v77+/v8/Pz5+fn4+PjwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAOAVkBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4gEigQMOwkDCCsMEQMOSAgDCYhpAp2dDzoBAgQrEQIOmkcHAaSbZ50ACQIDIg8FAxIiBAEHALsHuw+UoAAItwOjJAwOAxGRBAoCvCQSA5W9BJTOuwgJpAS3Do0MAQMFoKsPzAEAq6QJAbYFkQDlDgGprlewEgIRAA8EFHBwql4yUbsEGEAm4MABAwbKJRsBIWLFAwkMzKIHwNQ9CIoEQCgXQJTGeAIJ/xYAUDEABAEICHQaoNGbNADIFLxUAEClKFr69nmC0KiAgEYVDZJCiLDnqH6amopAUDBgLmQljBZgBcBor3aiiBktGY3qgACmWN0MqJYdVpYCAAjgKRdo0CqdCCpo9BZrU6YHR/2d6OumTLdxlUV4KeDBWxFSkZUsKfMs5cOF2+JMjHWWCM938cZFtrIfytIiA0RLuHSUzAIEkLUSYUABOJibS0SQQICghH4RdpWc2A+2MAAQvUmwye4w5r5xXz6QZTe0FFgPBWhyoLHAOGQQjLJW6tTAy9nFdqZ6DFmjAUv1ohl4IDV+p5XGOil4gNn5TejFRINMddYVWAQB/IkCn/+BDA4hi0IRNNLghBRWaOGFGGao4YYcdujhhyCGKOKIJJZo4okYEsARDQdIEIAEEtKAgIsJxIjiGQj8dANDItngCWg3nsEQgTI8wAADq9WgyQGwBIlGZTpE8xUNvd3k5BlQ4tDPgjQ8UtCVZmRpA0H/5CAbmGTMKBIjNRilAGVUjkRQQ2iOwSNhMvxopQwHMLZfnYAGKuighBZq6KGIJqrooow26ooiOkB6g6SOVlFSKOzccGmllmaKw6Y2gMqpFKKG6mkNpY76RKo0sBqDq6ouAeurp7Zaa6xNzAqDri3wimsRvvZ6qwzB/ipEsSsgi4KyxvrA7LLD0tqsE8+eUC3/Cdf+sAh6guR335TURkusuC9k68OPBuQDCAIGLNAABQ0sYAC4TJg7gr328oDdeTmC0u8eBSwwwQgTLLDSquTumrCwVDQpy0o0EQDBXnsI0EAJF0gz2cYcd+zxxyBzbE3IJItsWckhj4zyyixvjF6TUCKp0Yp4CFBBCRZo3PLOKKvMc8c+/1xS0EIXDecIDvsjgil0VXwxCQ0kFi6mny6MRCcEZDRvLAIpDbDABBsMRb71WJ2s2Ub8OE8xCxmk7h0PuQuvvPTKivbZVTd6gFHfRkE2vndP28PfgVtbuOBU5wA44nYnbirjShCeN+RISK7p4ZSjirkJi2duhOWPew7s/+YldC76EKBrnrm3AtXtwrbQOq465OzKHe/WeXqSLuekY9t72ZQHPLAIBR8cw76j/IsJl6E3j7jFGOuMcitJQ2yAxHtePjnjNuMsfcnUJxazAt39DtnvZA8KPdRSw5B0mUynbmvwYBMvdu5ZQ9TLwwqZD7z2kIvbu27nOhaoLRLsooWCZDc/yu3NEwUo4PYA6LzTAUF+M0ifBWOnOPT5b4McnGADQfgDDI6LhBf0n+lQyAMTSouFg1OhB2EYQwZm8IOJYl0EbThCGMBOg4eq3QDp1kEeGlB3I9mg8MJmvArO7nhx6ZM0lBcPyK1vBFEz2mSIVjQugmw21cPJ9SZmo/9pdY8EFPie0Lz4MzZ6DIzi84zMcGPFp2GxfU+koPsSIwv4zSVzS7RfE/PoxBZgLSM34V+ZGCfAueFOj4U84n22kkC3OZBvrTPiCSFJQ0728JOdjOQmRRnKF4rwhqUsoipJmUoXuFBhrfQkKmUZS1fK8JQ9sIY1YAS5V5YLhyfoBFpEUsY66VCChtPkL4fQJIIEoJKieNuJhOhIZJbulrTUAcw8wz/moSiQACjYSFbmxp2Vk5wn0yLH4KgL0DANTVcUQc5Ydk56pnON91Tn0eSSGKNoYo40Q9EZR5DGZa6SkOeaRTTKFLGKFNNE8QRA1AyKS1OmsCT0oCIxggTO4lH/NJu2TGUjCfhRVjJMpJjcYUkROspattSkLAAiDH0ZUpfOsqKwtOlLWWpRndYUpyv1Kd4OCkqhqoCmJzVqUkG6VKUeFZspeIQ1gpNMpx7zmso0yFmiIU2ZIo6aJL0XVJd1EwYoZBKjYMBJnNrR+50vq6LIlGwYUBGaRACY3LOjCLK4xXziM2QJkWsymKQdrwpuoCJI48bqiU7AxrUYfwRAPwywFbw+T68SbR9NRaEAZBjgGf6QRUTYWr9wuvV/QPXFZGokAhc1ohqWFdxIiSjWrDbVpw/sm+9sG9PYkhCpvXXqbYvaU+FWNbXDNe5uiXpT5R6XqcF1bgihO1Tp8o63/9W17nKRG13jXhW11H2qEnSJi4cSCqxEBG520yYNUxBFUW1diXrFm4RmTrFt0VQfZjNWDr+20b8tY6w+ucLPdtKim4RCLADmKeCSNRhkD9Zi+Ay8tMjqtwQTnW8KDKuCJvkTAAAlVHzBC9P1FmEmCxVBQw1gXifNdmsanu7nJpPRKv5rULnNJIl5mlPtbje8G/YtCGP8XB/vmLg9NvKRm4tk5xL5ukp+K3N3qt0nYzXKS6Zycas81ibnAXah2dR3g7plPqBLmoe4FHofmdwk/wF5KrJxFQlxqRGT2c1+CGNDKUZndkSUr43VYoQHTOgBT7gwtAhxIS6lYMXaU52DLv+0pIt26D5WuGl9lgtmJ3rnTufhkPrjmlEWOYg6l9ajnm6zHg7INgVqZ9HseLE1r1xipW4qxypNdXeVbOUfG7nXtcUysKUc5WFn2cldZrKPjc3hISdby9JltpA3yKsx+1rZXF7Bmuu2wos+s5cJs/O1ob0DFHtNcLr6sxojbbJJu6zAXdEOJtjhGDQzKt03Q+O6Afxod8OpSQGhhW/aFqt0bxqPx/5pELYJFM+2eFG6Enewa12DJj12MyzGla5kDWWK00CY7m3EwCGg8YXh2nXd/gF5eTlvgGSi4M8uc7RjjudsT1nmyMYufYtNc107VdpYTrjPd87rniv814H77rP/pNqMrQQdWdsWurVmoZov8RwGI37WY83KYlMwwjwP1ymy1C11zllprnVls3HHnm+CSiPCrREsKQhrb1vfTd393VncIUuXyQ5y7XfL+uE4y5DmhDZ7gIcBx58lHHzcQ7IBeG3kZx6DkxObxzm/ec2tC3RhG13Vyu381TU/dKOKvug6D/LTP79rpKdexsvGprVNrARWO0pyUQf9iUehNYcQoBcMUNGhJCdxojOhScBB0l4K8Nnh31LdjU8Zv/39boazjauIklyjBePg6VP/34kJyMHemf3nH/zoS4Dz9V/tfKoVX/VPODOIFbB8OhZKchzXPRHA3I7fg1j4hmI5lod+/zbHXbTHeax3gJRHegSIgK9XZLH3gB2Hegyofz+XgMYXgZo3exMXB43HWhriQrlHa3FAeAoRUBTiQu9XdmbwWFTBE8zQCwXgHQ3iQngHNN73fTrIFRd3Hg8BAQTBLdZhg22XWGqUdzuYhB+zd5vxDcKUgjFHdhMIB1sHEY0gE4hXICp4aqfVgVRIddj3gwSxUQbiQvlHgnDAdFTVEwMggzTIIK80gFOogQaYgQUIZLB3hx4HgXqIeQ24gHUIf6MXiHnogBXYenSIh3xoiIS4iIAIZFfVbA6iS2uIIvO1bZJ4LGDIficyX/GViUGwdWfldWr1XiAyX+rGbkr4RQYhd/90tRBq1yGoWIQAkEaquIpv1IoqNlidUHchiIE3WAYuGFl+NyKeyIWVJYxz4VmgFQGyMG2AMF+yBopA8IES4lqQF3YWomGWR42ec3qud4gKmHmNOId96GUWaHcSiIaJuIfmaF2UMilCKAPxGHT2eI/4mI/6uI/82I9BwgDwQDozgg/aqAIDCYI+xi4K5SOeQCR7NBNKVhY4sCRN0iXtUJHW9YLR8HcxUCW945FGJhMg8RK+yAJe4k0xcJJGZha6uCN4QgNn4mPR8ADnEScBMCezhgISc5OdkJM+hQAvsTss4idkWHlE6Y9ImZRKuZRM2ZRO+ZRQGZVSOZUbFHytAAz/BVkCj4CCNOAYkBCSnZAL9VEuL1kDTDISPqlTWMhiCOEOYPEO8VAJk/CVoiABM0gP4CCXscALEgAutoALFfZyI8AA1QCYUnUOtXALVJWX4gBizHAWolMZAoEQ/fEfcyEfOaFVAQARAJESAoFxhCF+BGEJO8ElyOAA3NEV9yAlDxMAWyGan0k+N4lpkHMYpiAblYkYmZEbTRGEY1F1m1FGRoEUBrCbI0AVZdILqzAAq9EPI6EJvxkNyGEAd5WWo3IYaoU1uZkbzxEXgxEb0pMbJQAgmDEC5dkO5pEAXlcPDMEM4WkM8mGdlYIZopA8/SMZ3GmZBiEBD8CZxYEg/8Ae/60lDeJnnCMAEQ9Ak68BngQgAQ6QNQLxn8eRCeDJlc1SnkmiF2mRn7ppEnNBD1X3mQIqAtwhEFeIeN5CC6ZgHqPwANFgovbxmXyjACVJlTZ6oziao3RQCS/Ao0fgo9YFJAbkkOLZAiMaTEQqOvAgD3gZDsH3bfAAYvhQF+SwJHN2L80AGlKVC9AgDd/gpCBWmLwRDVzBmBJSDrcJQzmxE505EAJBFZZQFlZRFwBAPpLFiU6xFZ4xmkaxHBqRCbAJMafAHYgEqJ65Ej4hpCD0Fi8Rb2QRFzpBFXJCJ54RFklBArXxGbRQG8NBC28RnTDhNb3wqRojnZlKpywEIJIxGacdcQpACAGwqqkX+RLMAxqeMRerJZ6rShnZAx0bg6qKukEAIqH/EBACwBt5IaubYX+7OB2eMRZZgxgPoCbG8Q8ISpObMa3Emq3UoaackRghejAzgxx0pKU9UgIIICByFAHuQW8aIZYvih98Qwv9eawxih/qmqTKRRA1qqMuYIX+GrACO7AEW7AGe7AIm7AKu7AM27AO+7AQG7ESO7EUW7EWe7EYmwQhAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The first round (prevalence screening) detects prevalent cases. The second and third rounds (incidence screenings) detect incident cases. In the figure, it is assumed that the test detects all cases and that all people in the population are screened. When this is not so, cases that are missed in the first round are available for detection in subsequent rounds, and the yield would be higher.",
"    <div class=\"footnotes\">",
"     O: onset of disease; Dx: diagnosis time, if screening were not carried out.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fletcher RH, Fletcher SW. Prevention. In: Clinical Epidemiology - The Essentials, 4th ed. Lippincott Williams &amp; Wilkins, Baltimore 2005. Copyright &copy; 2005 Lippincott Williams and Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_4_19533=[""].join("\n");
var outline_f19_4_19533=null;
var title_f19_4_19534="Proarrhythmia with class Ic antiarrhythmic drugs in CAST";
var content_f19_4_19534=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Encainide and flecainide increase cardiac mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 238px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Results of the Cardiac Arrhythmia Suppression Trial (CAST) in patients with ventricular premature beats after myocardial infarction. Patients receiving encainide or flecainide had, when compared to those receiving placebo, a significantly lower rate of avoiding a cardiac event (death or resuscitated cardiac arrest) (left panel, p = 0.001) and a lower overall survival (right panel, p = 0.0006). The cause of death was arrhythmia or cardiac arrest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Echt DS, Liebson PR, Mitchell B, et al. N Engl J Med 1991; 324:781.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_4_19534=[""].join("\n");
var outline_f19_4_19534=null;
var title_f19_4_19535="Minimum dose heparin in HD";
var content_f19_4_19535=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic diagram showing minimum dose heparin regimen in hemodialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic diagram illustrating the minimum dose heparin regimen for anticoagulation during hemodialysis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_4_19535=[""].join("\n");
var outline_f19_4_19535=null;
